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 Mitocôndria: o elo comum que desencadeia a patologia da βA e Tau na doença de 
Alzheimer 
 
Resumo 
A disfunção mitocondrial tem sido largamente implicada na etiologia da doença de 
Alzheimer (DA). Tendo em conta que a mitocôndria está implicada num vasto número 
de processos celulares, tem-lhe sido atribuída uma posição central na cascata de eventos 
que conduzem à neurodegeneração observada na forma esporádica da DA. É consensual 
que o peptídeo β-amilóide (βA) adicionado extracelularmente é captado pelas células 
induzindo citotoxicidade. Tendo em conta este facto usámos uma linha humana clonal 
com origem em neuroblastoma, SHSY-5Y, a qual foi exposta ao peptídeo βA1-42. Nestas 
condições observámos uma redução nos níveis de ATP bem como um decréscimo na 
actividade do complexo IV da cadeia respiratória mitocondrial (COX). Para além das 
alterações descritas, o rácio NAD+/NADH estava aumentado após exposição das células 
ao petídeo βA1-42. Estas alterações a nível mitocondrial, induzidas pelo petídeo βA1-42, 
afectam a rede microtubular onde aumentos de tubulina livre e modificações pós-
traducionais da Tau estão implicadas. Observámos que os níveis de acetilação da 
tubulina estavam diminuídos em células expostas aos petídeos βA. Está descrito que a 
sirtuina 2 (SIRT2), um membro da família de desacetilases, requer nicotinamida 
adenina dinucleotídeo (NAD+) para a sua activação. A SIRT2 tem como substrato 
preferencial a tubulina o que nos levou a propor a hipótese de que o aumento de NAD+ 
induzido pelos peptídeos βA poderá activar a SIRT2 culminando na ruptura da rede de 
microtúbulos. Como consequência desta disfunção microtubular o transporte axonal 
ficará comprometido. Constatamos, através da determinação dos níveis das isoformas 
 da proteína “microtubule-associated light chain 3” (LC3), LC3I e LC3II a activação da 
macroautofagia. Visto que aumentos nos níveis de LC3II são indicadores da activação 
da macroautofagia pudemos concluir que o peptídeo βA usado activa e altera o processo 
autofágico, uma vez que este mecanismo protector necessita de uma rede microtubular 
funcional para que as vesículas autofágiacs (VAs) sejam transportadas até aos 
lisossomas. Estas observações guiaram a investigação com base na hipótese de que o 
uso de agentes estabilizadores dos microtúbulos poderá constituir uma estratégia 
terapêutica para a DA. Verificámos uma redução nos níveis da hiperfosforilação da Tau 
em células pré-tratadas com uma concentração não tóxica de taxol. Este pré-tratamento 
com taxol impediu também o aumento dos níveis de LC3II. De acordo com estas 
observações, o taxol revelou eficácia na redução de oligómeros de βA nas fracções 
citosólicas, reduzindo também a activação de caspases 9 e 3. Os petídeos βA citosólicos 
são endereçados para a mitocôndria promovendo a sua disfunção. Taxol foi eficaz em 
reduzir os rácios anormais de NAD+/NADH, melhorar os níveis de retenção 
mitocondrial de rodamina 123. O resultado mais interessante, que indícia a importância 
de uma nova terapêutica ao nível dos microtúbulos, mostrou que o taxol reduziu o 
conteúdo mitocondrial de oligómeros de βA. As observações descritas apontam para 
que uma terapêutica a nível microtubular é eficaz em restabelecer o transporte 
retrógrado de mitocôndrias e de VAs, permitindo que mitocôndrias disfuncionais e 
agregados proteicos possam ser degradados por macroautofagia. Em paralelo, usámos 
células SHSY-5Y ρ0, depletadas do seu DNA mitocondrial mas que conseguem manter 
o ∆Ψm e os níveis de ATP. Observámos que estas células ρ0 têm níveis reduzidos de 
tubulina acetilada o que aponta para uma disfunção ao nível da dinâmica dos 
microtúbulos. Esta alteração ao nível dos microtúbulos correlaciona-se com um 
aumento dos níveis de Tau hiperfosforilada o que foi revertido com um tratamento de 
 24h com taxol. No que respeita à autofagocitose verificamos que não está alterada nesta 
células. Embora as células sem DNA mitocondrial tenham alterações em proteínas 
associadas aos microtubulos (tubulina acetilada e Tau hiperfosforilada) como mantêm 
os níveis de ATP, conseguem assegurar o tráfego intracelular. 
 
Palavras chave: Doença de Alzheimer, mitocôndria, βA, Tau, autofagia. 
 
 Mitochondria: the common up-stream driver of Aβ and Tau pathology in 
Alzheimer´s disease 
 
Summary 
Mitochondrial dysfunction has been widely implicated in Alzheimer´s disease (AD) 
etiology. Since mitochondria control a wide range of cellular processes the up-stream 
position of this organelle in the cascade of events leading to neurodegeneration in AD 
has been recognized. It is generally accepted that amyloid β-peptide (Aβ) added 
extracellulary is up-taken by cells and induces cytotoxicity. In this regard we used a 
clonal human neuroblastoma cell line, SHSY-5Y, which was exposed to Aβ1-42. In this 
case we observed a reduction in ATP production and a reduction in the activity of 
mitochondrial respiratory chain complex IV (COX). Further, NAD+/NADH ratio was 
increased in cells exposed to Aβ1-42. These mitochondrial alterations induced by Aβ1-42 
affect the microtubular network by inducing an increase in free tubulin and Tau post-
translational modifications. Moreover, we observed that tubulin acetylation levels where 
decreased in cells exposed to Aβ. It is documented that SIRT2, a member of the sirtuin 
family of deacetylases, requires nicotinamide adenine dinucleotide (NAD+) for their 
activation. SIRT2 has as preferential substrate tubulin which made us hypothesize that 
Aβ-induced NAD+ increase levels, may activate SIRT2 which could induce a 
microtubule network breakdown. In consequence of microtubule cytoskeleton collapse 
axonal transport becomes compromised. We accessed macroautophagy by evaluating 
microtubule-associated light chain 3 (LC3) isoforms, LC3I and LC3II. Since higher 
LC3II levels are indicator of activated macroautophagy, we could conclude that Aβ was 
able to simultaneously activate and impair autophagy. Such observations guided the 
 investigation based on the hypothesis that microtubule stabilizing agents can constitute 
a strategy for AD therapy. We verified a reduction in Tau hyperphosphorylation levels 
in cells pretreated with non toxic concentrations of taxol. Moreover, we could prevent 
LC3II levels from rising with taxol pretreatment. In accordance, taxol successfully 
reduced Aβ oligomers in cytosolic, and reduced caspase 9 and 3 activation. Cytosolic 
Aβ is reported to be imported by mitochondria where exerts further toxicity. Taxol 
reduced NAD+/NADH abnormal ratios, ameliorated mitochondrial rhodamine 123 
retention and, most interesting, mitochondrial Aβ oligomers content were significantly 
reduced. These observations point out that an intervention at a microtubule level may be 
effective in restoring mitochondrial and AVs retrograde transport, enabling damaged 
mitochondria and protein aggregates to be degraded by the lysosomes. In parallel, we 
used SHSY-5Y ρ0 cells which are mtDNA depleted, but maintain ∆Ψm and ATP levels. 
We found that these ρ0 cells have reduced levels of acetylated tubulin which entail 
microtubule dynamics impairment. Furthermore these cells showed high levels of 
hyperphosphorylated Tau which was ameliorated with 24h treatment with taxol. Taking 
into consideration autophagocytosis we found no significant alterations between 
mtDNA depleted cells and parental cells. So, although we found alterations in related 
microtubule proteins (acetylated tubulin and Tau hyperphosphorylation) we speculate 
that ATP levels maintenance allowed these cells to maintain their intracellular traffic.  
 
Keywords: Alzheimer´s disease, mitochondria, Aβ, Tau, autophagy. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1  
Introdution  
 
 
 
 1.1 General introduction  
Mitochondria are uniquely poised to play a key role in neuronal cell survival or death 
because they are regulators of both energy metabolism and apoptotic pathways (Duchen 
et al., 2004) (Fig. 1). In fact, this organelle plays an important role as ATP producers, as 
regulators of intracellular calcium homeostasis and producers of endogenous reactive 
oxygen species (ROS). Like no other cellular organelle, mitochondria possess their own 
DNA (mtDNA) that encodes the subunits of the oxidative phosphorylation (OXPHOS) 
system (Fukui & Moraes, 2008). Since respiratory chain is not completely efficient, 
ROS are produced during aerobic respiration, for instance, superoxide anion that can be 
converted into other ROS species such as hydrogen peroxide (Balaban et al., 2005; 
Fukui & Moraes, 2008). Since ROS production occurs during normal cellular 
metabolism in cells, the ageing process is associated with a marked decline in 
mitochondrial function, characterized by a decrease in OXPHOS and ATP synthesis, an 
increase in mtDNA mutations, an increase in abnormal mitochondrial cristae structures 
and a marked rise in free radical production (Lin & Beal 2006; Shi et al., 2008).  
 
  
 
Fig.1. ROS production by mitochondria. ROS can damage mitochondrial 
proteins, membranes, DNA, impairing the ability to produce ATP and other 
metabolic functions. Mitochondrial oxidative damage can induce the release 
cytochrome c into the cytosol and activate apoptotic cell death cascades. 
Mitochondrial ROS may act as modulatable redox signal, reversibly 
affecting the activity of a range of functions in mitochondria, cytosol and 
nucleos. Overall, mitochondria is likely to contribute to a wide range of 
pathologies (adapted from Murphy et al., 2009).  
 
 In this point of view, ageing is considered the pivotal risk factor for the development of 
Alzheimer´s disease (AD) (Swerdlow & Khan 2004; Lin & Beal 2006; Swerdlow and 
Khan 2009). These late onset sporadic (SAD) forms of AD arise among all genetic 
forms of the disease, manifesting in late stages of the life although it is believed that 
genetic and environmental factors act synergistically in the onset of the disease 
(Anandatheerthavarada et al., 2003; Pereira et al., 2005). Since AD is a progressive and 
chronic condition and actually there are no available therapeutics that can alleviate, or 
even cure the disease, the involvement of mitochondria in a wide range of cellular 
processes opens new windows for the identification of new therapeutical targets.  
 
1.2 Age-related Alzheimer´s disease 
Mutations dominantly inherited in presenilin-1 (PS-1), presenilin-2 (PS-2) and amyloid 
precursor protein (APP) allowed to explain the early-onset familial forms of AD (FAD) 
although, only a small percentage of patients exhibit this familial trait (Laws et al., 
2003). The vast majority of AD patients develop this condition later in life where 
mutations are rarely found (Shepherded et al., 2009). Characterized to be multi-factorial 
and heterogeneous, sporadic AD may be the result of stochastic driven ageing process. 
Ageing exerts a deleterious effect on brain activity and there have been some clues 
stating environmental and epigenetic variations that contribute to AD pathology 
(Cacabelos et al., 2005). Genetic analyses suggest that there are likely to be several 
genes exerting influence in the susceptibility of an individual to AD (Mattson 2004). 
The ε4 allele of the apolipoprotein E (apoE) gene (APOE) was identified as a major risk 
factor for late-onset AD across populations (Laws et al., 2003, Raber et al., 2004; Reddy 
& McWeeney 2006; Belinson & Michaelson 2009; Bu 2009). ApoE plays an important 
 role in the metabolism of lipoproteins and cholesterol and has been associated with 
increased deposition of Aβ, brain inflammation, impaired neuronal plasticity and repair 
(Belinson & Michaelson 2009). Even though, the correlation between the presence of 
ApoE alleles and the emergence of AD sporadic cases is well documented, their 
products, even present in homozygosity, are not determinant for AD development 
(Laws et al., 2003). Besides, in the vast majority of AD sporadic cases the referred 
alleles are absent. The etiology of AD remains elusive and, in the last years, the first 
steps have been taken in order to find therapeutic targets that allow a true beneficial 
outcome, since this disease represents a major health problem in developed societies, 
and is predicted to increase disproportionately as the global elderly population increases 
(Howel et al., 2005).  
 
 
1.3 Mitochondrial dysfunction involvement in AD  
Proposed by Swerdlow and Khan (Swerdlow & Khan 2004), the mitochondrial cascade 
hypothesis enabled to compass some handicaps of another proposed theory for AD 
etiology, the Aβ cascade hypothesis proposed by Hardy and Selkoe (2002). Hardy and 
Selkoe stated the primordial event in AD etiopathology was the production of Aβ 
peptides, from APP processing. The accumulation of these peptides in brain culminated 
in generalized neurodegeneration observed in AD (Fig. 2). Most recently, many authors 
affirmed that this theory should be applied in cases of early-onset AD (Selkoe 2001; 
Cummings & Cole 2002; Swerdlow & Khan 2004; Swedlow 2007).  
 
  
Fig.2. The amyloid cascade hypothesis. Mutations in APP, PS1 and PS2 
genes provide a genetic framework for the emerging of AD. (adapted from 
Hardy and Selkoe, 2002).  
 
On the other hand, mitochondrial cascade hypothesis relies on the central idea that 
similar mechanisms underlie brain ageing and AD (Swerdlow 2007). Mitochondrial 
dysfunction is believed to occupy an upstream position in the pathogenesis of the 
disease, giving rise to the histopathological and pathophysiological features of AD 
(Swerdlow & Khan 2004). Supporting Swerdlow and Khan point of view is the 
systemic mitochondrial dysfunction in AD, which cannot simply represent a 
consequence of neurodegeneration (Swerdlow 2007). In addition, inherited polymorphic 
 variations of mtDNA together with the age-related mitochondrial changes determine a 
functional threshold that induces AD-characteristic histopathology (Swerdlow & Khan 
2009). The bridge between mitochondrial cascade hypothesis and Aβ cascade 
hypothesis is mitochondrial dysfunction and consequent ROS overproduction (Fig. 3). 
 
 
 
Fig.3. Mitochondrial cascade hypothesis. Age-related mitochondrial deficits 
drives a functional threshold that give rise to AD-characteristic 
histophatologies, including processing of APP to Aβ (adapted from 
Swerdlow and Khan, 2009).  
 
Over the years many evidence have been presented in order to unify the cellular 
processes responsible for ageing, mitochondrial dysfunction and, consequently, 
neurodegenerative disease such as late onset AD. A number of studies have 
demonstrated that mitochondrial integrity declines with age (Shigenaga et al., 1994), 
 affecting multiple systems in the brain such as memory, learning and sensory processes 
(Aliev et al., 2009; Boumezbeur et al., 2010). Age-dependent mitochondrial 
abnormalities consist in decline in mitochondrial function, namely decrease in oxidative 
phosphorylation and ATP synthesis, such as an increasing in ROS production and 
accumulation of mtDNA mutations (Cortopassi & Wong 1999; Beal 2005; Shi et al., 
2008). Experiments performed with platelets from AD subjects, age-matched controls 
and young control subjects showed that mitochondrial membrane potential was higher 
in young controls than both AD patients and aged control subjects (Shi et al., 2008). 
Furthermore, AD subjects and age-matched controls showed tolerance to the addiction 
of Aβ in opposition to young controls suggesting a response to a chronic mild 
stimulation. Recently, Boumezbeur and colleagues (2010) used magnetic resonance 
spectroscopy to access neuronal mitochondrial metabolism of healthy elderly and young 
volunteers. It could be concluded that during healthy ageing occurs a reduction in 
neuronal mitochondrial metabolism and altered glial mitochondrial metabolism, in 
comparison with young subjects, which may be responsible for declines in brain 
function. Taken together, these observations point to mitochondrial dysfunction 
occurring during ageing what can predispose elderly individuals to age-related 
disorders. To further support the rational of mitochondrial dysfunction as an early event 
in AD etiology, Mild Cognitive Impairment (MCI) subjects have been studied. MCI is 
considered a nosological entity or a translational state between normal ageing and AD 
(Morris et al., 2008; Padurariu et al., 2010). In fact, the early markers of metabolic 
dysfunction observed in AD have also been found in MCI subjects, such as 
mitochondrial DNA (mtDNA) oxidative damage, reported as a major risk for AD 
development and progression (Hirai et al., 2001; Swerdlow & Khan 2004; Manczak et 
al., 2004; Migliore et al., 2005). Studies made in lymphocytes showed significantly 
 higher levels of primary oxidative mtDNA damage in lymphocytes from AD and MCI 
subjects compared with control subjects (Migliore et al., 2005). Further, deficits in 
mitochondrial electric transport chain (ETC) have been verified, particularly in 
cytochrome c oxidase (COX) platelets from MCI subjects in agreement with 
observations made in platelets from AD patients (Valla et al., 2006). More recently, 
changes in oxidative stress markers were detected in serum from MCI subjects. A 
positive correlation was detected between the decreased antioxidant defense and 
increased lipid peroxidation in AD and MCI patients when compared with age-matched 
controls (Padurariu et al., 2010). Altogether, these data gathered from healthy elderly 
people and MCI subjects leave open the possibility that mitochondrial dysfunction 
occur a priori of symptom onset and it is possible that other pathological changes also 
take place before the disease manifestation (Valla et al., 2006). Furthermore, 
observations from AD patients report a defective activity of COX in early stages of the 
disease. COX activity was found to be decreased in platelets from AD subjects whereas 
the protein subunits are normally present (Cardoso et al., 2004) and this fact is not a 
consequence of tissue degeneration, ROS-induced membrane damage, deficient 
antioxidant defenses neither decreased synthesis rates. This data supports the idea that 
mitochondrial dysfunction is a primary or at least a non-amyloid dependent process 
(Cardoso et al., 2004). Fibroblasts from sAD patients revealed a greater amount of 
abnormal mitochondrial morphology and distribution when compared to age-matched 
normal human fibroblasts (Wang et al., 2008). These studies performed in peripheral 
blood allowed to suggest that AD can constitute a systemic disease affecting several 
tissues. Observation from post mortem AD brain samples revealed an increased 
oxidative damage and decreased COX activity (Bosseti et al., 2002), lower percentage 
of normal mitochondria and a higher percentage of the mitochondria with broken cristae 
 compared with age-matched  controls (Hirai et al., 2001; Wang et al., 2009). Important 
was the fact that the described abnormalities were detected in neurons lacking of 
neurofibrillary tangles (NFT) and before Aβ deposition (Hirai et al., 2001). In order to 
further complete this amount of evidence that place mitochondria in an upstream 
position in AD etiology, AD cybrid cell lines (cytoplasmic hybrid) have shown to 
correlate in many ways to AD pathophysiology, for instance, decreased COX activity 
(Swerdlow et al., 1997; Cardoso et al., 2004), decline in bioenergetics over time in 
culture and decrease viability in comparison to control cybrids (Onyango et al., 2005). It 
is well accepted that changes observed in AD cybrids recapitulate the early events of the 
disease (Trimmer et al., 2004). Cybrid technique was first described by King and 
Attardi (1989) and is based on the central idea that cybrid cells lines result from the 
repopulation of a host mtDNA depleted cell (ρ0) with different mtDNA, having the 
same nuclear background.  
 
1.4 AD: a disorder of protein misfolding 
Independent of its etiology, AD is characterized clinically by chronic and progressive 
dementia, including severe memory loss, profound changes in behavior and personality, 
incapacitating patients even in their daily tasks (Pereira et al., 2005). Histopathological 
hallmarks are intracellular NFT of abnormally phosphorylated Tau; neuropil threads, 
dystrophic neurites and extracellular senile plaques composed of Aβ (Iqbal & Grundle-
Iqbal 2008) (Fig. 4).  
 
 A B
 
Fig.4. AD Histopathological hallmarks. (A) Senile plaque of Aβ. (B) 
Neurofibrillary tangles of hyperphosphorylated Tau. (adapted from Maccioni 
et al., 2001). 
 
The presence of the referred hallmarks in AD brains is a necessary prerequisite for the 
definitive postmortem diagnosis of AD. Anatomically, AD brains are characterized by a 
severe atrophy which correlates with a reduction of cell density in brain regions 
involved in learning and memory, as a consequence of generalized degeneration of 
synapses and death of neurons (Mattson 2004). The course of AD neurodegeneration is 
initiated in the entorhinal cortex and spreads to the hippocampus, temporal cortex, 
frontoparietal cortex and, at last, to subcortical nuclei causing severe dementia (Reddy 
& McWeeney 2006). Since the first description of an AD patient by Alois Alzheimer, 
some decades were required to finally isolate and identify AD related brain areas and 
histopathological hallmarks (Small & Duff 2008). This isolation allowed inferring that 
senile or neuritic plaques are mainly composed of deposits of amyloid fibrils 
surrounded by dystrophic neuritis, activated microglia and reactive astrocytes 
(Sorrentino & Bonavita 2007). More specific, in AD brains Aβ is concentrated around 
meningeal and cerebral vessels and in the gray matter as Aβ plaques (Götz et al., 2004). 
 Aβ is a 4kDa proteolytic fragment that presents more often two carboxyl-terminal 
variants of Aβ: Aβ1-40 mainly secreted from cultured cells and found in cerebrospinal 
fluid and Aβ1-42 which is the main component of amyloid deposits in the brain (Neve et 
al., 2000), resulting from cleavage of amyloid-β precursor protein (βAPP) (Selkoe 2001; 
Reddy & McWeeney 2006). APP is a type I integral membrane glycoprotein through a 
single transmembrane domain (Evin et al., 2003; Mattson 2004) which possesses a large 
extracellular glycosylated N terminus and a shorter cytoplasmic C terminus (Marlow et 
al., 2003). Aβ region is located at the cell surface or in the luminal side of endoplasmic 
reticulum (ER) and Golgi membranes where part of the peptide is anchored. Along the 
secretory pathway APP is cleaved sequentially by β-secretase (BACE) at the N-terminal 
end (Marlow et al., 2003) originating sβAPP fragment and a membrane-associated C-
terminal fragment, βCTF (Sambamurti et al., 2002; Mattson 2004; Yu et al., 2004). 
Then suffers cleavage by γ-secretase, a proteolytic complex composed of presenilin, 
nicastrin, APH-1 and PEN-2 (Götz et al., 2008) at the C-terminal of βCTF, in the 
amyloidogenic pathway (Anandatheerthavarada et al., 2003; Mattson 2004) originating 
a series of beta-sheet containing peptides, the Aβ peptides (Pereira et al 2005). The 
second classical neuropathological lesion present in AD brains is NFT which consist in 
intracellular bundles of abnormal fibers aggregated into paired helical filaments (PHF) 
(Selkoe 2001; Sorrentino & Bonavita 2007). NFT were found to be mainly composed of 
an abnormally hyperphosphorylated form of the microtubule-associated protein, Tau. 
Tau physiological functions inside the cell include the assembly and stabilization of 
microtubules (Götz et al., 2004; Zhang et al., 2009). Other roles have been attributed to 
Tau, such as signal transduction, organization of neuronal cytoskeleton, intracellular 
axonal transport, generation of cell polarity and shape and anchoring of phosphatases 
and kinases (Maas et al., 2000; Götz et al., 2004; Sorrentino & Bonavita 2007). These 
 structures are found in cell bodies, apical and distal dendrites and in dystrophic neurites 
associated with amyloid plaques (Götz et al., 2008). In an AD context it was shown that 
Tau was phosphorylated 3 to 4 folds higher due to the activity of some groups of 
kinases like, glycogen-synthase kinase-3β (GSK-3β), cyclin-dependent protein kinase 5 
(cdk5), c-AMP protein dependent (PKA) and stress activated protein kinases (Gong & 
Iqbal 2008). The result of an augmented phosphorylation is a change in its 
conformation, the dissociation of Tau from microtubules, and a potential increase in 
toxicity (Götz et al., 2008; Zhang et al., 2009). Ultimately, these changes in microtubule 
conformation affect morphology and biological functions of neurons (Zhang et al., 
2009). 
 
1.5 Mitochondrial metabolic control of Sirtuin 2 regulation 
Mammalian sirtuins are homologues of the silent information regulator factor 2 (Sir2), 
first described in Saccharomyces cerevisiae (Denu 2005; Michan & Sinclair 2007). 
These proteins have been found in organisms from all domains of life, ranging from 
prokaryotes to humans (Outeiro et al., 2008; Julien et al., 2009). The sirtuin (SIRT) 
family is composed of seven members (SIRT1-SIRT7) who are characterized by the 
presence of an approximately 200-amino-acid core (Vaquero et al., 2006) that require 
nicotinamide adenine dinucleotide (NAD+) for their enzymatic activity. These proteins 
catalyze mainly deacetylation reactions in a variety of substrates including histones, 
transcription factors and apoptotic modulators (Michan & Sinclair 2007; Outeiro et al., 
2008; Yu et al., 2009). Although the molecular mechanisms underlying the ageing 
process are not fully understood, in the last years a body of evidence emerged pointing 
to sirtuins as mediators of life extension, described in a wide range of organisms 
 including yeast, insects and rodents (Outeiro et al., 2008; Han 2009). Since it is 
recognized that ageing and neurodegenerative diseases such as AD are intimately 
connected, the understanding of sirtuin-mediated pathways can, in the future, provide 
feasible therapeutic targets in the treatment and prevention of such conditions (Han 
2009). It is consensual that sirtuins differ in their sub-cellular localization, where 
SIRT1, SIRT6 and SIRT7 are predominantly in the nucleus, SIRT3, SIRT4 and SITR5 
in the mitochondria, whether SIRT2 resides mostly in the cytoplasm (Michan & Sinclair 
2007). Various cellular functions have been attributed to SIRT2 for instance its 
translocation to the nucleus during the G2/M phase where deacetylation of histone H4 
takes place (Yu & Auwerx 2009). SIRT2 can be found associated with the microtubule 
network showing affinity to acetylated tubulin as a substrate, in comparison to 
acetylated histone (North et al., 2003). North and colleagues (2003) demonstrated using 
GFP-SIRT2 that SIRT2 deacetylated Lys40 of α-tubulin which co-localize with the 
microtubule network. In the same experiments, using SIRT2 knockdown mice it was 
shown that tubulin was hyperacetylated. Even though sirtuins have been related with 
some potential protective effects, not everything is perfect in the sirtuin world. In fact, 
SIRT2 activation has been reported to promote cell death (Han 2009). In acute or 
chronic neurodegenerative diseases, it has been described alterations in mitochondrial 
metabolic function and oxidative stress. Indeed, it is evident an impairment of the main 
mitochondrial enzymes, resulting in ATP depletion (Mattson 2000) which can be 
attributed to an increase in ROS production (Pereira et al., 1999; Butterfiled & 
Lauderback 2002). Among these mitochondrial enzymes, pyruvate dehydrogenase 
(PDH) and α-ketoglutarate are vulnerable to oxidative modification due to their 
sulfhydryl groups (Pocernich & Butterfield 2003). Since these enzymes are responsible 
for the conversion of oxidized NAD+ into NADH, which is vital to mitochondrial 
 respiration and oxidative phosphorylation, their inhibition by acrolein result in higher 
levels of NAD+. Acrolein was shown to be augmented in AD brains comparing with 
age-matched controls and it was proved that it could inhibit state 3 respiration without 
reducing mitochondrial complexes I-IV activity (Porcernich & Butterfield 2003). In 
parallel, age-related reductions in mitochondrial respiratory chain and increase in ROS 
production have also been described (Prihar et al., 2008; Brewer 2000). Parihar and 
collaborators (2008) demonstrated that in neurons from aged rat there was a significant 
decline in resting NADH concentration, when compared with embryonic and middle-
aged neurons, which have a larger pool of NADH for metabolism. Furthermore, Chong 
and collaborators (Chong et al., 2005) demonstrated that nicotinamide (NIC), a known 
inhibitor of sirtuin activity could reduce anoxia-induced neuronal injury in primary 
hippocampal rat neuronal cultures and increase cell viability, preventing caspase 
activity, reducing DNA fragmentation and increased phosphorylation of proteins like 
Akt and Bad, preventing apoptosis. Of course, only indirectly we can infer that, at least 
part of these results is due to SIRT2 inhibition. More recently, studies made in 3xTg-
AD mice found that NIC was able to prevent cognitive deficits by the inhibition of brain 
sirtuins associated with increased levels of deacetylated tubulin (Green et al., 2008). 
Further, 3xTg-AD mice at 8 months of age have high levels of Tau phosphorylation in 
serine and threonine residues. Remarkably, treatment with NIC could significantly 
reduce Thr231-phosphoTau . Since acetylation of tubulin, a primary substrate of SIRT2 
was implicated in NIC-dependent results, we can infer that SIRT2 inhibition by NIC 
results in neuroprotection in this AD model.   
 
 
 1.6 Mitochondrial metabolic control of microtubule network  
Neurons are highly differentiated cells with extensive synapses, branched dendritic 
arbors, and axons that can achieve a considerable size. Communication between the 
synapses and cell body is crucial for neuronal functioning and survival in a way that 
neurons are susceptible to disruption of microtubule-dependent transport (Trimmer & 
Borland 2005). It has been widely documented that AD neurons have changes at 
cytoskeleton level and a reduction of assembled microtubules is evident when compared 
with control cases (Cash et al., 2003; Santa-María et al., 2005). Disruption in 
microtubule dynamics results in incapacity of many subcellular processes to go on 
which conducts to retrograde degeneration accompanied by synaptic loss and neuronal 
cell death (Li et al., 2007). Studies performed in AD retinoic acid-differentiated cybrids 
showed that the velocity of both mitochondrial and lysosomal transport along neurites 
was significantly reduced when compared to differentiated control cybrids (Trimmer & 
Borland 2005). This result suggests a disruption in the transport machinery of both 
organelles in consequence of dysfunctional mitochondria contained in AD cybrids. 
Further evidence point to mitochondrial dysfunction and associated ROS production 
induced changes in the redox equilibrium, having a straight influence on microtubule 
disassembly (Santa-María et al., 2005). Cash and co-workers (2003) found, in brain 
biopsies of AD patients, alterations in the microtubules of pyramidal neurons, 
mitochondrial abnormalities and increase oxidative damage, before detectable changes 
in Tau. ROS overproduction can affect microtubules in such way that quinones are 
likely to be involved. It was found in cell culture experiments that the interaction 
between tubulin-quinone resulted in a decrease of microtubule polymerization rather 
than in microfilaments (Santa-María et al., 2005). In non pathological situations there is 
 a finely regulated balance between kinase and phosphatase activation that seems to be 
broken in AD (Ebneth et al., 1998). Indeed, it was shown that Aβ could bind to Tau in 
solution which potentiates GSK3β activation and Tau phosphorylation impairing its 
physiological function (Guo et al., 1998). When Tau is not available to play its normal 
role cells can suffer serious damage due to microtubule deficient organization. Various 
studies showed that Tau over-expression induced changes in cellular shape, loss of 
polarization and delayed cell growth, where mitochondrial distribution is dramatically 
altered and acquiring a clustered aspect (Ebneth et al., 1998). Further studies, using Tau 
over-expression models, concluded that cells presented shorter neurites with impaired 
microtubule transport which promoted an increased sensitive to oxidative stress due to 
lower mitochondrial content (Stamer et al., 2002; Mandelkow et al., 2003). 
 
1.7 Mitochondrial metabolic control of the autophagic-lysosomal pathway  
In age related diseases like AD, protein oligomerization and aggregation are prominent 
features that trigger neuronal disturbances including over-activation of macroautophagy 
(Cardoso et al., 2009) (Fig.5). Macroautophagy, herein referred as autophagy, is a 
degradative pathway of the lysossomal system that allows the removal of cellular 
organelles and long-lived proteins (Boland et al., 2008).  
 
  
 
Fig.5. Abnormal aggregated proteins clearance. If a protein cannot be 
refolded by molecular chaperones it is targeted to the endosome/lysosome 
system or proteasome degradation. Alteratively, protein aggregates may 
suffer retrograde transport along microtubule network towards the centriole 
where they can form an aggresome which can be ultimatly degraded by 
macroautophagy. (adapted from Ross and Poirier, 2005).   
 
Autophagy is a tightly regulated process that begins with the formation of a cytosolic 
membrane under the control of multiple proteins, including microtubule-associated light 
chain 3 (LC3). This complex controls the membrane elongation that sequestrates a 
region of the cytoplasm into a double membrane autophagic vacuole (AV) or 
autophagosome (Levine & Kroemer 2008). The degradation of sequestered materials is 
completed when AVs fuse with lysosomes (autophagolysosomes), process that allows 
the acidification and acquisition of proteolytic enzymes (Yu et al., 2005; Nixon 2007; 
 Klionsky 2008). First described as a mainly starvation inducible process, it is now 
recognized the constitutive role of autophagy in the brain (Nixon 2007). This “self-
eating” process is crucial for cellular maintenance providing essential elements for 
cellular metabolism (Cuervo 2004). Further, it is well documented that the 
autophagosome-lysosome pathway (ALP) is simultaneously impaired and induced in 
AD brains (Nixon 2007). AVs accumulate within dystrophic neurites in AD brains and 
in AD animal models, suggesting a progressive dysfunction of ALP process (Yu 2005; 
Nixon et al., 2005) and consequently protein aggregates turnover is blocked. Low levels 
of mRNA of beclin 1, a protein required for induction of autophagy in vivo, have been 
documented in MCI subjects and AD patients (Lee & Gao 2008; Pickford et al., 2008). 
In APP mice model this low level of beclin 1 is also verified and is associated with 
enhancement in Aβ pathology, where impaired autophagy may be involved (Pickford et 
al., 2008). Likewise, mitochondrial dynamics impairment has been widely implicated in 
neurodegenerative disorders such as AD (Chan 2006). Mitochondria are degraded by 
the autophagic process, herein referred as mitophagy (Chen and Yan 2007). It was 
verified an increase in mitochondrial degradation products in vulnerable AD neurons, 
suggesting an augmented mitochondrial turn-over by mitophagy (Moreira et al., 2007). 
Electron microscopic analyses of AD brain samples, lipoic acid (LA) and COX-1 
revealed that LA become associated with AVs in opposition to control cases. These 
observations demonstrated that mitochondria are key targets of autophagy in AD 
(Moreira et al., 2007). A close interaction between AVs accumulation and Aβ 
deposition has been demonstrated. Endosomes and AVs, isolated from a variety of 
tissues, showed to be enriched in APP and APP secretases, namely γ-secretase 
components most precisely PS1 and nicastrin, needed to generate Aβ peptides (Yu et 
al., 2004; Mizushima 2005). This impairment in ALP leads to an exacerbation of Aβ 
 production known to exert cytotoxicity (Boland et al., 2008). Yang and co-workers 
(2008) reported that activated caspase-3 was found within dystrophic neurites, most 
exactly in AVs associated with amyloid plaques in PS/APP mice. Pro-apoptotic proteins 
will accumulate and apoptotic cell death can take place culminating in the 
neurodegeneration process observed in AD brains. Valid proofs have been presented 
pointing to the link between Aβ-mediated toxicity and mitochondrial dysfunction. Aβ 
species have been found associated with mitochondria in human AD brains (Hirai et al., 
2001; Caspersen et al., 2005; Manczak et al., 2006; Devi et al., 2006). Many studies 
showed that Aβ added extracellularly can act intracellularly promoting mitochondrial 
dysfunction (Anandatheerthavarada et al., 2003; Hansson Petersen et al., 2008) by 
lowering enzymatic activities. Aβ treatments in isolated rat brain mitochondria induced 
deficits in energy metabolism (Chen & Yan 2007; Casley et al., 2002). Data obtained 
using PC12 and NT2 cells showed that Aβ peptides decrease the activity of MRC 
complexes (Pereira et al., 1999; Cardoso et al., 2001). PC12 cell line bearing APP 
Swedish mutation (APPsw PC12) showed a decreased in COX activity and failure in 
other MRC enzymes, when compared with wild type APP bearing cells or empty vector 
transfected cells (Keil et al., 2004). Furthermore, it was demonstrated that Aβ is targeted 
to mitochondria, and arrested by TOM-40, one of the mitochondrial translocase proteins 
being the transport towards the inner membrane assured by translocase of the inner 
membrane (TIM) (Anandatheerthavarada et al., 2003; Hansson Petersen et al., 2008). 
Along with the described effects of Aβ in mitochondrial metabolism, mitochondrial 
fusion and fission is also compromised. Abnormal mitochondrial fission results in 
fragmented and bioenergetically impaired mitochondria (Barsoum et al., 2006). Studies 
using cerebrocortical neurons in culture exposed to Aβ, showed an increase in S-
nitrosylation of Drp1 (Westermann 2009) culminating in SNO-Drp1 dimmer formation, 
 similar to those found in AD brain patients (Cho et al., 2009). The formation of such 
dimmers results in augmented GTPase activity favoring mitochondrial fragmentation 
process and neuronal synaptic activity failure (Cho et al., 2009). To further address the 
role of APP and Aβ causing mitochondrial dysfunction and consequent neuronal cell 
death through modulation of mitochondrial fusion and fission, M17 cells were 
transfected in order to over-express APPwt or APPsw. APP over-expression induced 
fragmentation and abnormal mitochondrial distribution in both constructions of 
transfected M17 cells (Wang et al., 2008). After all, oxidative damage is one major 
trigger of mitochondrial dynamics impairment. In primary cortical neuronal cultures 
submitted to NO donor, SNOC, uncontrolled fission revealed to be an upstream and 
early event in SNOC-mediated neuronal cell death. The augmented rate of fission could 
be followed by 3D time-lapse fluorescence imaging, where it was evident the 
fragmentation of mitochondrial into several isolated organelles (Barsoum et al., 2006). 
Normal human fibroblasts treated with H2O2 increased cellular ROS, induced dynamin-
like protein 1 (DLP1) reduction, which regulates mitochondrial fission and distribution. 
The alteration in distribution of mitochondria was comparable to what was observed in 
sporadic AD fibroblasts (Wang et al., 2008). As discussed before, mitochondrial 
dysfunction triggers abnormalities along microtubule cytoskeleton that can be 
responsible for AVs retrograde transport impairment, towards the cell body where 
lysosomes are located. In support, it has been shown that microtubule depolymerizing 
agents disrupt vesicular transport inducing rapid accumulation of AVs (Kolchl et al., 
2006). In opposition, microtubule polymerizing agents prevent cognitive deficits in AD 
mice model (Matsuoka et al., 2008). Directly affecting mitochondria some uncouplers 
were shown to disturb mitochondrial dynamics (Cappelleti et al., 2005). In post-mitotic 
cells the continuous accumulation of oxidative damage, triggers the accumulation of 
 non-functional mitochondria, process that induces autophagy. Besides, damaged 
oxidative-modified proteins potentiate lipofuscin accumulation into the lysosome 
(Zheng et al., 2006). Lipofuscin is a polymeric material composed of oxidatively 
modified protein and lipid residues, which decreases lysosomal capacity and sensitizes 
cells to oxidative stress (Terman et al., 2006). Such evidence point to an interplay 
between mitochondrial dysfunction, impair microtubule network, and activation of the 
autophagic process, which creates a positive feedback loop where AVs are being 
continuously produced and accumulated due to lack of degradation within lysosomes 
(Cataldo et al., 1996; Yu et al., 2005; Cardoso et al., 2009). 
 
1.8 Therapeutic intervention at microtubule network level 
Along with new insights in the molecular and genetic mechanisms that underlying AD 
pathology, over the years there has been intense search for drugs that could slow the 
neurodegeneration process. The efficacy of therapeutic agents tested under clinical trials 
was not good, so it seems important to adjust pharmacological intervention to the 
elucidation of the still unclear molecular pathogenic events in AD and to disclosure new 
ways to achieve earlier diagnosis (Michaelis et al., 2003). Since one major hallmark of 
AD is the deposition of plaques of Aβ and hyperphosphorylation of Tau, many efforts 
have been taken regarding the process of misfolded protein accumulation. In this regard, 
the disruption of microtubule network induced Tau hyperphosphorylation led to propose 
that microtubule stabilizing agents may prevent neuronal dystrophy (Lee et al., 1994). 
In a rat model it was demonstrated that taxol protects cortical neurons from toxicity by 
Aβ25-35, decreasing calpain activation and cdk5/p25 complexes formation (Li et al., 
2003). Pretreatment with taxol showed to be effective in preventing Tau 
 hyperphosphorylation (Michaelis et al., 2002) and in reducing Aβ-induced apoptosis 
(Chen et al., 2001). Further, Michaelis and colleagues (2005) tested various 
microtubule-stabilizing agents which demonstrated protective effects against the Aβ25-35 
and Aβ1-42 peptide found in AD brains plaques. Endoplasmic reticulum (ER) stress has 
been widely implicated in Aβ-mediated toxicity (Nakagawa et al., 2000; Ferreiro et al., 
2006). Microtubule stabilizers were able to reduce early events in ER stress response to 
Aβ and thapsigargin treated cells (Seyb et al., 2006). These results suggest that 
microtubule integrity avoid unfolded protein response (UPR) activation and 
consequently ER stress responses. Besides protein oligomer and fibril accumulation, 
synaptic failure with loss of essential synaptic components is intimately associated with 
dementia of AD (Butler et al., 2007). The disruption of microtubule cytoskeleton by 
accumulation of proteins leads to axonopathy and synaptic pathology (Butler et al., 
2007). In hippocampal slice model of lysosomal dysfunction it was found that 
pretreatment with TX67, an analogue of taxol, restored acetylation levels of tubulin, 
which is considered a good indicator of microtubule stability. TX67 was also able to 
restore pre and post synaptic proteins levels, rescuing hippocampal synapses in such 
model (Butler et al., 2007). Although taxol and analogues showed potential therapeutic 
application for AD, it is known to have little effectiveness in the access to the central 
nervous system (CNS) (Liu et al., 2002). Moreover, a systemic taxol delivery is 
associated to the activation of apoptotic cell death in dividing cells (Divinski et al., 
2006). Studies using a vasoactive intestinal peptide (VIP) showed that this compound 
induce neuroprotective effects, stimulating glial cells to produce neurotrofic factors that 
mediate neuroprotection (Gozes et al., 2005). NAP is an eight amino acid peptide 
derived from activity-dependent neuroprotective protein (ADNP), one of the neurotrofic 
factors that mediate VIP protective effects (Gozes et al., 2005; Vulih-Shultzman et al., 
 2007). Remarkably, NAP was shown to be able to cross blood brain barrier after 
systemic or intranasal administration (Gozes et al., 2005), protecting neurons even in 
the absence of glial cells (Zemlyak et al., 2000). Tackling the target of NAP-induced 
neuroprotection, this peptide was shown to interact with microtubule cytoskeleton after 
cellular internalization mimicking taxol neuroprotection effects (Divinski et al., 2004), 
improving microtubule reorganization and increasing neuritis number (Divinski et al., 
2006). In vitro and in vivo studies demonstrated that NAP is efficient in reducing Tau 
hyperphosphorilation in a variety of models (Gozes et al., 2004; Vulih-Shultzman et al., 
2007; Shiryaev et al., 2009). Using ADNP+/- mice which exhibit Tau pathology and 
correlated cognitive deficits, NAP was able to partially ameliorate degenerative features 
(Vulih-Shultzman et al., 2007). Moreover, in 3xTg-AD mice treatments with NAP 
induced a reduced Aβ accumulation and Tau hyperphosphorylation (Matsouka et al., 
2007; 2008). Further studies point to NAP being effective in neuroprotection against 
diverse insults. In fact this octapeptide protected newborn rat cortical neurons from Aβ1-
42 toxicity (Gozes et al., 2008). One indicator of mitochondrial dysfunction is the release 
of cytochrome c from mitochondria to cytosol that activates downstream caspases 
triggering cell death. NAP treatment in cortical neurons from rats submitted to oxygen-
glucose deprivation lowered the levels of cytochrome c release (Zemlyak et al 2009). 
This result lead to hypothesize that NAP uptaked by neurons stabilizes microtubules 
and offers protection against cytocrome c release related mitochondrial dysfunction and 
against apoptosis activation due to cytoskeleton damage (Zemlyak et al., 2009). This 
neuroprotective ability of NAP demonstrated in a wide range of experimental settings 
paved the path for clinical experiments. NAP is currently in phase II of clinical trials, by 
Allon Therapeutics Inc. in MCI subjects. Clinical tests results indicate an improvement 
in memory skills when compared with placebo treated subjects (Shiryaev et al., 2009).  
 1.9 Objectives of this study 
While the etiology of AD remains largely unclear, there is accumulating evidence from 
a variety of models that suggests mitochondrial dysfunction as prominent feature in 
disease etiology. Further, recent data suggests that Aβ deposition is potentiated by 
autophagic-liposomal pathway (ALP) impairment. In this regard the ultimate goal of 
this work consisted in address how mitochondrial dysfunction triggers ALP impairment. 
In this situation Aβ production and deposition becomes increased which potentiate Tau 
post-translational modifications and promotes cell death. The bridge linking these two 
events seems to be microtubule network breakdown. To address the importance of 
microtubule cytoskeleton in Aβ-mediated toxicity we tested the potential protective role 
of taxol, a microtubule stabilizing agent. To achieve these purposes we used two cell 
models: SHSY-5Y parental and SHSY-5Y ρ0 cell lines.  
 
 
 
 
 
 
  
  
 
 
 
   
 
 
 
 
 
 
 
Chapter 2 
Materials & Methods  
 
 
 
 2.1 Biological Material 
2.1.1 Cell lines  
 
2.1.1 Parental neuroblastoma cell line SHSY-5Y ρ+ 
SHSY-5Y human neuroblastoma cells containing mitochondrial DNA (ρ+) were 
purchased from ATCC. Cells were grown in 75 cm2 tissue culture flasks maintained in 
a humidified incubator at 37ΊC and 5% CO2. 
 
2.1.2 mtD>A depleted SHSY-5Y ρ0 cells 
The SHSY-5Y ρ0 cell line was depleted from mitochondrial DNA by long-term 
ethidium bromide exposure as described by Swerdlow and co-workers (1997). Cells 
were grown in 75 cm2 tissue culture flasks maintained in a humidified incubator at 37ºC 
and 5% CO2. 
 
2.2 Chemicals and Cell media  
Paclitaxel (taxol) and Nocodazole were obtained from Sigma (St. Louis, MO, USA). 
The synthetic Aβ1–42 peptide was obtained from Bachem (Bubendorf, Switzerland). 
DMEM medium was obtained from Gibco-Invitrogen. Non-dialyzed fetal bovine serum 
was obtained from Gibco-Invitrogen. SHSY-5Y ρ+ cell growth medium consisted in 
DMEM and Ham´s F12 medium with 10% supplemental non-dialyzed fetal bovine 
serum and 100 IU/ml penicillin and 50 µg/ml streptomycin. SHSY-5Y ρ0 cell growth 
 medium consisted of SHSY-5Y growth medium supplemented with 200 µg/ ml sodium 
pyruvate, 150 µg/ml uridine.  
 
2.3 Toxicity studies  
 
2.3.1 In SHSY-5Y ρ+ cells  
For the MTT assay, cells were plated in 24-well plates at a density of 0.1 ×106 
cells/well. For rhodamine 123 measurements, cells were plated in 24-well plates at a 
density of 0.05 ×106 cells/well. For ATP determinations, cells were plated in 12-well 
plates at a density of 0.2 ×106 cells/well. Immunocytochemistry was performed in cells 
grown on coverslips in 12-well plates at density of 0.05 ×106 cells/well. For 
measurements of caspase enzyme activities, Western blot analysis, determinations of 
electron transport chain (ETC) enzyme activities and NAD+/NADH levels cells were 
plated in petri dishes (10 cm) at a density of 2.5 ×106 cells/dish. For western blot, 
immunocytochemestry, rhodamine 123 and NAD+/NADH levels twenty-four hours 
after seeding of cells the medium was refreshed and taxol was added from a DMSO-
taxol stock solution with a final concentration of 2 nM. Four hours later Aβ1–42 was 
added in the same well/petri dish of the previous described taxol incubation with a final 
concentration of 1μM. Other wells/petri dishes were incubated with 5nM of nocodazole, 
1μM of Aβ1–42 and 2nM of taxol, respectively. The final concentration of DMSO in 
culture media did not exceed 0.05% (v/v) and under these conditions, no alterations in 
cell’s viability were observed. In the case of ETC activities and ATP determinations 
 cells were exposed to 1μM of Aβ1–42 for 24 hours. For all experimental procedures, 
controls were performed in the absence of the stress agents.  
 
2.3.2 In SHSY-5Y ρ0 cells  
To minimize cell death after plating, SHSY-5Y ρ0 cells were scrapped directly from the 
growing flask. However, the cell medium was refreshed before incubation with 2nM of 
taxol, during 24 hours. Controls were performed in the absence of taxol.  
 
2.4 Cell viability assay  
 
2.4.1 MTT reduction test  
Cell viability was determined by the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl) 
2,5-diphenyltetrazolium bromide) assay (Mosmann, 1983). In viable cells, the enzyme 
succinate dehydrogenase metabolizes MTT into a formazan that absorbs light at 570 
nm. Following the cell treatment protocol the medium was aspirated and 0.5 ml MTT 
(0.5 mg/ml) was added to each well. The plate was then incubated at 37 ºC for 3 h. At 
the end of the incubation period the formazan precipitates were solubilized with 0.5 ml 
of acidic isopropanol (0.04 M HCl/Isopropanol). The absorbance was measured at 570 
nm. Cell reduction ability was expressed as a percentage of the control.   
 
 
 
 
 2.5 Mitochondrial function evaluation  
 
2.5.1 Cytochrome c Oxidase (Complex IV) assay 
Complex IV activity was determined upon Aβ exposure using the method of Wharton 
and Tzagotoff (1967), which measures the oxidation of reduced cytochrome c by 
cytochrome c oxidase at 550 nm. To prepare reduced cytochrome c, cytochrome c was 
mixed with a few crystals of ascorbate and partitioned by a dialysis membrane 
overnight against 0.01 M phosphate buffer, pH 7.0 at 4 ºC. The reduced cytochrome c 
concentration was then determined using 0.1 M potassium ferricyanide. The reaction 
mixture contained 0.01 M potassium phosphate, pH 7.0, and 50 µM reduced 
cytochrome c. The reaction was initiated by addition of the sample at 30 ºC. The pseudo 
first order rate constant (K) was calculated, because the reaction is of first order with 
respect to cytochrome c. Results are expressed both as K per minute per milligram of 
protein.  
 
2.5.2 Analysis of adenine nucleotides 
Cells were extracted, on ice, with 0.4 M perchloric acid. Cells were next centrifuged at 
14,000 rpm for 5 min at 4 ºC. The resulting pellets were solubilized with 1 M NaOH to 
further analyse protein content by Bradford protein assay (Bio-Rad, Hercules, CA, 
USA). The resulting supernatants were neutralized with 5 M KOH and 2.5 M Tris, pH 
7–8, and then centrifuged at 14,000 rpm for 5 min at 4 ºC. These supernatants were 
assayed for adenine nucleotides (ATP, ADP and AMP) by reversed-phase HPLC as 
described by Stocchi et al. (1985). The chromatographic apparatus used was a Beckam 
Gold System, consisting of a 126 Binary Pump Model and a 166 Variable UV detector 
 that was controlled by computer. The column was a Lichrospher 100 RP-18 (5 lm) from 
Merk (Germany). An isocratic elution with 100 mM KH2PO4 buffer at pH 7.4 and 1% 
methanol was performed at a flow rate of 1.2 ml/min. The adenine nucleotides were 
detected at 254 nm for 5 min. 
 
2.5.3 Quantification of >AD
+
/>ADH levels 
Cells were harvested and assayed for NAD+/NADH levels using the MBL International 
Corporation Kit. Briefly, cells were resuspended in an extraction buffer. The cell lysates 
were incubated at 37 °C for 60 min with NAD cycling mix and NADH developer. Total 
NAD and NADH were detected by absorbance change at 450 nm. 
 
2.6 Apoptotic cell death evaluation 
 
2.6.1 Mitochondrial membrane potential (FΨm) analysis 
Changes in mitochondrial membrane potential were estimated using the fluorescent 
cationic dye rhodamine 123 (Rh123) (Sigma). After 24h treatment, cells were loaded 
with 0.5 µM Rh123 (in the dark, at 37 ºC) and the fluorescence (λexc = 505 nm and λem 
= 525 nm) was recorded during 45 min before, and also for 10 min after mitochondrial 
depolarization, using a Spectramax Plus 384 spectrofluoremeter (Molecular Devices). 
Maximal mitochondrial depolarization (∆ψm collapse) was performed in every 
individual experiment by adding 1 µM FCCP (protoionophore), which was always 
preceded by oligomycin (2 µg/ml) to prevent ATP synthase reversal. Rh123 retention 
was determined by the difference between total fluorescence (after depolarization) and 
 the initial value of fluorescence. Because positively charged Rh123 is retained by 
functional mitochondria with a high ∆ψm, a decrease of cellular retention of Rh123 has 
been associated with a decrease in ∆ψm. 
 
2.6.2 Caspases activation 
Caspase activation was measured using a colorimetric method described by Cregan et 
al. (1999), in which the substrate cleavage is monitored at 405 nm. After 24h treatment, 
cells were washed and placed in buffer containing 25 mM HEPES, 1 mM EDTA, 1 mM 
EGTA, 2 mM MgCl2, and protease inhibitors (0.1 M PMSF, 2 mM DTT, and a 1:1000 
dilution of a protease inhibitor cocktail). Cells were harvested by scraping and frozen 
three times on liquid nitrogen. The lysate was centrifuged for 10 min at 14,000rpm 4 ºC. 
The resulting supernatant was stored at -80 ºC. Protein concentrations were measured 
by the Bradford method. Lysates (50 µg of protein) were incubated at 37 ºC for 2 h in 
25 mM HEPES, pH 7.5 containing 0.1% CHAPS, 10% sucrose, 2 mM DTT, and 40 µM 
Ac-LEHD-pNA or 40 µM Ac-DEVD-pNA (Calbiochem) to determine caspase 9 or 
caspase 3 activation, respectively. 
 
2.7 Immunoblotting  
Individual cell lines were washed in ice-cold phosphate-buffered saline (PBS) and lysed 
in 2% Triton X-100 containing hypotonic lysis buffer (25 mM HEPES, pH 7.5, 2 mM 
MgCl2, 1 mM EDTA and 1 mM EGTA supplemented with 2 mM DTT, 0.1 mM PMSF 
and a 1:1000 dilution of a protease inhibitor cocktail). Cell suspensions were frozen 
three times in liquid nitrogen and centrifuged at 20,000×g for 10 min. To detect Tau 
 PHF, cell lysates were prepared using the lysis buffer, in the absence of Triton 
supplemented with 2 mM ortovanadate and 50 mM sodium fluoride.  
For the analysis of Aβ aggregates, the supernatants (Triton soluble fractions) were 
collected and saved and the pellets (Triton insoluble fractions) were ressuspended in 1× 
specific sample buffer (0.2 M Tris–HCl, pH 6.8, 40% glycerol, 2% SDS, 0.005% 
Coomassie). For the analysis of mitochondrial Aβ aggregates cells were washed with 
PBS, scraped in a buffer containing 250 mM sucrose, 20 mM Hepes, 1 mM EDTA, 1 
mM EGTA, and protease inhibitors (0.1 M PMSF, 0.2 M DTT, and 1:1000 dilution of a 
protease inhibitor cocktail) and homogenized. Cells were frozen three times on liquid 
nitrogen and the lysate was centrifuged at 2200 rpm for 12 min at 4 ºC. The resulting 
supernatant was centrifuged at 10600 rpm for 10 min at 4 ºC. Pellets resulting from this 
step constitute a crude mitochondrial fraction. Triton soluble fractions and 
mitochondrial fractions containing same amounts of protein were diluted (1:2) with 
sample buffer and were separated by electrophoresis on a 4–16% Tris–Tricine SDS gel 
(Klafki et al., 1996). 
To prepare soluble and polymeric tubulin fractions, cells were very gently washed twice 
with a microtubule stabilizing buffer (0.1 M N-morpholinoethanesulfonic acid, pH 6.75; 
1 mM MgSO4; 2 mM EGTA; 0.1 mM EDTA; 4 M glycerol). Soluble proteins were 
extracted for 4–6 min at 37°C in 100 µl of microtubule stabilizing buffer containing 1% 
Triton X-100. The remaining contents of the culture dish were scraped in 100 µl of 25 
mM Tris (pH 6.8) and 0.1% SDS. This suspension was frozen three times in liquid 
nitrogen (Joshi and Cleveland, 1989).  
The total amount of resulting cell lysates obtained were removed and stored at −80 °C. 
Protein content was determined using Bradford protein assay (Bio- Rad, Hercules, CA, 
USA).  
 For the SDS-PAGE experiments samples were resolved by electrophoresis in SDS 
polyacrylamide gels and transferred to PVDF membranes (Millipore, Billerica, MA, 
USA). For the PAGE experiments samples were not boiled to minimize disaggregation 
prior to electrophoresis. Non-specific binding was blocked by gently agitating the 
membranes in 5% non-fat milk or 5% BSA for phosphorilated proteins and 0.1% Tween 
in TBS for 1h at room temperature. The blots were subsequently incubated with the 
respective primary antibodies overnight at 4°C with gentle agitation (1:10,000 mouse 
monoclonal anti-alpha-tubulin antibody from SIGMA, 1: 1000 6E10 mouse monoclonal 
anti-Aβ, mouse anti-PHF-Tau (clone AT8; 1:250) and anti-Tau (1:400) from Pierce 
Endogen (Rockford, IL), 1:20000 mouse monoclonal anti-acetylated tubulin from 
SIGMA, 1:1000 rabbit polyclonal anti-SirT2 from Cell Signaling, 1:1000 rabbit 
polyclonal anti LC3B from Cell Signaling, 1:500 mouse monoclonal anti Beclin 1 from 
BD Biosciences, 1:300 mouse monoclonal anti-OXPHOS complex IV subunit I from 
Molecular Probes, 1:500 mouse monoclonal anti-glyceraldehyde-3-phosphate 
dehydrogenase from Millipore (Billerica, MA, USA). Membranes were washed with 
TBS containing 0.1% nonfat milk and 0.1% Tween three times (each time for 15 min), 
and then incubated with the appropriate horseradish peroxidase-conjugated secondary 
antibody for 2 h at room temperature with gentle agitation. After three washes specific 
bands of interest were detected by developing with an alkaline phosphatase enhanced 
chemical fluorescence reagent (ECF from GE Healthcare). Fluorescence signals were 
detected using a Biorad Versa-Doc Imager, and band densities were determined using 
Quantity One Software. 
 
 
 2.8 Immunocytochemistry 
 
2.8.1 Confocal microscopy visualization of LC3B and tubulin  
After 24h treatment parental SHSY-5Y parental and SHSY-5Y ρ0 cells were washed 
twice with PBS and fixed for 30 min at room temperature using 4% paraformaldehyde. 
The fixed cells were washed again with PBS, permeabilized with 0.2% Triton X-100, 
and blocked with 3% BSA. The permeabilized cells were incubated with primary 
antibody (1:2,000 monoclonal anti-alpha-tubulin from Sigma; and 1: 300 polyclonal 
anti- LC3B from Cell Signaling). Afterward cells were incubated 1h with appropriate 
secondary antibody (1:250 alexa fluor 594 and 488 from Molecular probes, Eugene, 
OR, USA). Finally cells were washed in PBS, incubated for 5 minutes with Hoechst 
33342 (15mg/L in PBS, pH 7.4) in the dark. Cells were visualized by confocal 
microscopy. 
 
2.9 Data analysis  
All data were expressed as mean ± SEM of at least three independent experiments 
performed in triplicate. Statistical analyses performed using one-way ANOVA followed 
by Bonferroni Multiple-Comparisons Procedure as post-hoc test or paired t-test. A P 
value < 0.005 was considered statistically significant.   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
Results 
 
 
 
 3.1 Aβ, taxol and nocodazole toxicity in SHSY-5Y ρ+. Aβ and taxol toxicity in 
SHSY-5Y ρ0. 
We used the ability of cells to reduce MTT as a parameter of cell viability, in order to 
establish a concentration of taxol and nocodazole that did not interfere with SHSY-5Y 
cells proliferation. In parallel, we established a concentration of Aβ that, despite being 
toxic, do not induce necrosis (Cardoso SM, PhD thesis). SHSY-5Y ρ0 were used to 
determine non toxic taxol concentrations. As previously described in NT2 ρ0 cells, Aβ 
did not induce alterations in SHSY-5Y ρ0 cells viability (Cardoso et al., 2001).  
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Fig.6. Effects of taxol, nocodazole and Aβ on MTT reduction. (A) SHSY-5Y 
ρ+ cells where incubated with 5nM, 2nM taxol; 5 nM nocodazole or 1µM of 
 Aβ1-42 mainly constituted of oligomeric forms. (B) SHSY-5Y ρ0 cells where 
incubated with 2 nM taxol or 1µM of Aβ1-42. Data are expressed as a 
percentage of the untreated SHSY-5Y cells, with the mean ± SEM from 
three independent experiments. ***p < 0.001, significantly different from 
the untreated cells.  
 
3.2 Mitochondrial function in SHSY-5Y ρ+ exposed to Aβ and in SHSY-5Y ρ0 
As previously described Aβ treated cells have lower COX activity than untreated 
SHSY-5Y ρ+ cells (Cardoso et al., 2001) (Table I). Moreover, SHSY-5Y ρ0 cells had 
no detectable COX activity (data not shown). ATP levels, in SHSY-5Y ρ+ cells 
exposed to 1µM of Aβ1-42, decreased approximately 35 % as compared to untreated 
cells. In ρ0 cells, ATP levels were similar to those measured in ρ+ cells (Fig. 7A).  
Table I 
Complex IV activity(K/min/mg) 
Untreated  0,000562 ± 0,000101 
Aβ  0,000384±0,000118* 
 
Activity of mitochondrial respiratory complex IV (COX) in SHSY5Y 
untreated cells and exposed to 1µM Aβ. * P < 0.05, significantly different as 
compared to untreated SHSY5Y cells. 
 
We further analyzed NAD+/NADH ratio in ρ+ and ρ0 cells. We observed that Aβ 
exposure significantly increased the levels of NAD+ in ρ+ cells which was prevented by 
 pre-treatment with taxol. Nocodazole also induced an increase in NADH to NAD+ 
turnover (Fig. 7B). These observations are in accordance with the hypothesis that Aβ 
peptides added extracellulary are up-taken by cells and are targeted to the mitochondria, 
where exerts further toxicity (Anandatheerthavarada et al., 2003; Hansson Petersen et 
al., 2008). Interestingly, NAD+/NADH ratio was significantly increased in untreated 
ρ0 cells as compared to untreated ρ+ cells. Similarly to what we observed in Aβ treated 
ρ+ cells, taxol partially prevented the increase in NAD+ levels in untreated ρ0 cells (Fig. 
7C). 
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Fig.7. (A) ATP levels in SHSY-5Y ρ+ and ρ0 cells untreated and ρ+ cells 
exposed to 1µM Aβ. ATP levels where measured by HPLC as described in 
 Materials and Methods. Data are expressed as a percentage of untreated ρ+ 
cells values, with the mean ± SEM derived from triplicate determinations 
from four independent experiments. *p < 0.05 significantly different 
compared with ρ+ untreated cells. (B) NAD+/NADH ratio in SHSY5Y ρ+ 
cells incubated with taxol, nocodazole and Aβ as described in Materials and 
Methods. (C) NAD+/NADH ratio in SHSY5Y ρ0 cells incubated with taxol, 
as described in Materials and Methods. Data are expressed as absolute 
values, with the mean ± SEM derived from three independent experiments. 
*p < 0.05 ; **p < 0.01; ***p < 0.001, significantly different compared with 
ρ+ untreated cells.  
 
3.3 Activation of the intrinsic apoptotic pathway 
Rhodamine 123 retention reflects the status of the mitochondrial membrane potential, 
and declines as the mitochondrial membrane potential is dissipated. As shown in Fig. 
8A, Aβ treatment decreased rhodamine 123 retention in ρ+ cells. Taxol was able to 
ameliorate this Aβ-induced decline in mitochondrial membrane potential in ρ+ cells. 
Similar to Aβ induced alteration in rhodamine 123 retention, nocodazole treatment led 
to a decrease in mitochondrial membrane potential. ρ0 cells were able to maintain 
mitochondrial membrane potential, although not statistically significant. Taxol 
treatment increased rhodamine 123 mitochondrial retention in ρ0 cells (Fig. 8C).  
A decrease in mitochondrial membrane potential induced by Aβ peptides can activate 
the mitochondrial apoptotic pathway (Cardoso et al., 2002). In order to clarify if Aβ-
mediated insult activated the intrinsic apoptotic pathway in our cellular model, we 
showed that Aβ and nocodazole exposure significantly activated caspases 9 and 3. Pre-
 treatment with taxol was able to reduce Aβ–mediated caspases 9 and 3 activation (Fig. 
8C and D). 
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Fig.8. Mitochondrial membrane potential and caspase 9-like and caspase 3-
like activation in SHSY-5Y cells, incubated with taxol, nocodazole and Aβ. 
(A) Mitochondrial membrane potential was expressed as the percentage of 
rhodamine 123 retention in ρ+ untreated cells, with the mean ± SEM values 
derived from four independent experiments. **p < 0.01, ***p < 0.001 
significantly different as compared to untreated cells. (B) Mitochondrial 
membrane potential in SHSY-5Y ρ0 was expressed as the percentage of 
rhodamine 123 retention in ρ+ untreated cells, with the mean±SEM derived 
from three independent experiments. Caspase activity was measured 
spectrophotometrically at 405 nm, as described in Materials and Methods. 
(C) Caspase 9 activation was determined by Ac-LEHD-pNA cleavage. (D) 
Caspase 3 activation was determined by Ac-DEVD-pNA cleavage. Data 
 represent the mean ± SEM values derived from five independent 
determinations. * P < 0.05, significantly different as compared to untreated 
SHSY-5Y ρ+ cells. 
 
3.4 Mitochondrial metabolism alteration drives microtubule network disruption. 
Aβ-mediated mitochondrial dysfunction led to an increase in NAD+ levels, a well 
known sirtuin cofactor. Moreover, SIRT2, a tubulin deacetylase, have been associated 
to alpha-synuclein induced toxicity (Outeiro et al., 2007). We accessed SIRT2 
activation indirectly by determining tubulin acetylation levels, since tubulin is a 
substrate of this enzyme. SIRT2 expression levels were similar in our cellular models 
(Fig. 9).  
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Fig.9. SIRT 2 expression in SHSY-5Y ρ+ and SHSY-5Y ρ0 cells. (A) and 
(B)  Densitometry and  Western blot analysis of Sirtuin 2 levels in SHSY-5Y 
ρ+ cells untreated or incubated with taxol, nocodazole and Aβ after 
correcting with GAPDH. (C) and (D) Densitometry and Western blot 
analysis of Sirtuin 2 levels in SHSY-5Y ρ0 cells untreated or incubated 
incubated with taxol, after correcting with GAPDH.  
 Since tubulin acetylation levels are a good indicator of microtubule stability (Butler et 
al., 2007), we evaluated SIRT2-induced alterations in acetylated tubulin levels in our 
models. Aβ treatment decreased tubulin acetylation in SHSY-5Y ρ+ cells, similarly to 
what we observed by nocodazole treatment. Accordingly to our previous results, taxol 
pretreatment in ρ+ and ρ0 cells reversed the decrease in acetylated tubulin levels (Fig. 
10). 
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Fig. 10. Acetylated tubulin in SHSY-5Y ρ+ and SHSY-5Y ρ0 cells. (A) and 
(B) Densitometry and Western blot analysis of acetylated tubulin levels in 
SHSY-5Y ρ+ incubated with taxol, Nocodazole and Aβ, after correcting 
with GAPDH (C) and (D) Densitometry and Western blot analysis of tubulin 
acetylated levels in SHSY-5Y ρ0 cells untreated and exposed taxol, after 
 correcting with GAPDH. Data are expressed as the increase over untreated 
SHSY-5Y cells and represent mean ± SEM values derived from at least three 
independent determinations. * p < 0.05; **p < 0.01 significantly different as 
compared to untreated SHSY-5Y ρ+ cells. ## p < 0.01 significantly different 
as compared to untretaed SHSY-5Y ρ0 cells, ### p< 0.001 significantly 
different as compared to SHSY-5Y ρ+ cells exposed to Aβ. 
 
Confocal microscopy analysis of tubulin showed that Aβ is able to induce microtubule 
network disruption being this structure less defined, similar to what we observed in 
nocodazole treated cells (Fig. 11A). ρ0 cells showed similar tubulin patterns as 
compared to untreated ρ+ cells (Fig. 11B).  
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Fig. 11. α-tubulin staining in SHSY-5Y ρ+ and SHSY-5Y ρ0 cells. (A) α-
tubulin staining in SHSY-5Y ρ+ untreated or incubated with taxol, 
Nocodazole and Aβ. (B) α-tubulin staining in SHSY-5Y ρ0 cells untreated 
or incubated with taxol.  
 
Since microtubule dynamics is dependent on the availability of ATP, Aβ-induced ATP 
levels reduction and tubulin acetylation decrease compromise proper microtubule 
dynamics. These effects were confirmed by determining free tubulin levels by western 
blot analysis (Fig. 12A and B).  
 Taxol as microtubule targeted drug that stabilizes assemblies was effective in reducing 
free tubulin in the presence of Aβ, which can be visualized by immunocytochemistry 
(Fig. 11A) and western blot analysis (Fig. 12A and B). 
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Fig. 12. Free tubulin in SHSY-5Y ρ+. (A) and (B) Densitometry and 
Western blot analysis of free tubulin in after correcting with GAPDH. Data 
are expressed as the increase over untreated SHSY-5Y cells and represent 
mean ± SEM values derived from at least three independent determinations. 
* p < 0.05 significantly different as compared to untreated SHSY-5Y ρ+ 
cells. 
 
Evidences from our group, shown that Aβ1-42 induces Tau hyperphosphorylation in 
cortical neurons (Resende et al., 2008). We further supported this evidence in our 
 cellular model (Fig. 13A and B). Taxol pre-treatment showed efficacy in reducing Tau 
phosphorylation at Serine 202 residue. Moreover, we showed that nocodazole was also 
able to induce slightly Tau hyperphosphorylation. Data obtained in ρ0 cells point to a 
non statistical increase of Tau hyperphosphorylation (Fig. 13C and D). Our results 
indicate that microtubule depolymerization potentiates Tau post-translational 
modifications. 
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Fig. 13. Alterations in Tau hyperphosphorylation upon taxol, nocodazole 
and Aβ exposure. (A) and (B) Densitometry and Western blot analysis of 
PHF Tau/Tau ratio in SHSY-5Y ρ+ cells. (C) and (D) Densitometry and 
Western blot analysis of PHF Tau/Tau ratio in SHSY-5Y ρ0 cells. Data are 
 expressed as the increase over untreated SHSY-5Y cells and represent mean 
± SEM values derived from at least three independent determinations. **p < 
0.01 significantly different as compared to untreated SHSY-5Y ρ+ cells. 
 
3.5 Impairment of macroautophagy triggered by microtubule alterations.  
Growing evidence indicate that basal macroautophagy is essential for maintenance of 
cellular homeostasis through the degradation of mal-functioning organelles and protein 
aggregates. Since beclin-1 is required for macroautophagy induction we evaluated its 
expression in our cell models. We found no alterations in ρ+ cells with or without 
treatments (Fig. 14). 
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Fig. 14. Beclin levels in SHSY-5Y ρ+ cells. (A) and (B) Densitometry and 
Western blot analysis of Beclin levels after correcting with GAPDH.  
 
In view of the fact that Aβ-driven microtubule dynamics impairment compromises AVs 
transport we evaluated the levels of LC3II, which are indicators of a stimulation of 
 macroautophagy. We observed an up-regulation of macroautophagy in Aβ treated cells 
that were partially prevented by taxol pretreatment (Fig. 15A and B). Data obtained in 
ρ0 cells indicated no significative alterations in autophagocytosis (Fig. 15C and D) 
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Fig.15. LC3II alterations in SHSY-5Y ρ+ and SHSY-5Y ρ0 cells. (A) and 
(B) Densitometry and western blot analysis of LC3II levels in SHSY-5Y ρ+ 
 cells incubated with taxol, Nocodazole and Aβ after correcting with 
GAPDH. (C) and (D) Densitometry and western blot analysis of LC3II 
levels in SHSY-5Y ρ0 cells untretated or exposed to taxol after correcting 
with GAPDH. Data are expressed as the increase over untreated SHSY-5Y 
cells and represent mean ± SEM values derived from at least three 
independent determinations.* p < 0.05 significantly different as compared to 
untreated SHSY-5Y ρ+ cells. 
 
Confocal images merging α-tubulin and LC3B showed that in Aβ treated cells LC3B 
fluorescence (green) is most spread along cells and has increased fluorescence 
indicating a possible activation of ALP pathway (Fig. 16).  
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 Fig. 16. LC3B staining alterations in SHSY-5Y ρ+ and SHSY-5Y ρ0 cells. 
(A) LC3B staining alterations in SHSY-5Y ρ+ cells untreated or incubated 
with taxol, Nocodazole and Aβ. (B) LC3B staining alterations in SHSY-5Y 
ρ0 cells untreated or exposed to taxol.  
 
3.6 Microtubule stabilizer reduced Aβ oligomerization and mitochondrial Aβ 
content.  
After 24 h incubation Taxol decreased Aβ triton insoluble oligomers in SHSY-5Y ρ+ 
cells, which indicated that microtubule breakdown inhibited Aβ clearance (Fig. 17).  
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Fig.17. Cytosolic Aβ monomers/oligomers content in SHSY-5Y ρ+. (A) and 
(B) Densitometry and westernblot analysis of cytosolic Aβ 
monomers/oligomers content in cells exposed to taxol, nocodazole and Aβ 
after correcting with GAPDH. Data are expressed as the decrease over 
SHSY-5Y cells exposed to Aβ and represent mean ± SEM values derived 
from at least three independent determinations. * p < 0.05 significantly 
different as compared to Aβ treated SHSY-5Y ρ+ cells. 
 We have also showed that taxol could reduce mitochondrial Aβ (Fig. 18). This evidence 
point out to the crucial role of microtubule network for the degradation by ALP of 
damaged mitochondria loaded with Aβ peptides. 
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Fig.18. Mitochondrial Aβ monomers/oligomers content in SHSY-5Y ρ+. (A) 
and (B) Densitometry and westernblot analysis of mitochondrial Aβ 
monomers/oligomers content in cells exposed to taxol, nocodazole and Aβ 
after correcting with COX. Data are expressed as the decrease over SHSY-
5Y cells exposed to Aβ and represent mean ± SEM values derived from at 
 least three independent determinations.* p < 0.05 significantly different as 
compared to Aβ treated SHSY-5Y ρ+ cells. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
Discussion 
 
 
 
 In this study we investigated the role of mitochondrial dysfunction in molecular events 
leading to protein missfolding and deposition in an AD cellular context. We provide 
evidence that mitochondrial dysfunction is up-stream in the cascade events that lead to 
cell demise, namely trigger microtubule network breakdown and macroautophagy 
impairment.  
We started our work showing that Aβ1-42 could induce a bioenergetics failure and 
alterations in NAD+/NADH ratio levels. Lower ATP and higher NAD+ levels could 
induce microtubule disassembly, where SIRT2 is likely to play a major role. 
Furthermore, we showed that taxol could prevent tubulin cytoskeleton damage induced 
by Aβ1-42 rescuing cells from apoptotic cell death. Remarkably, Aβ oligomerization and 
mitochondrial Aβ content where reduced in the presence of taxol.  
From AD patients brains and platelets to AD cellular models COX deficiency is a 
prominent pathological feature (Mancuso et al., 2003; Bosseti et al., 2003; Cardoso et 
al., 2004). Moreover, mitochondrial abnormalities have been found early in the disease 
progression, before amyloid deposition or NFT formation (Hirai et al., 2001). In our 
model which consisted in SHSY-5Y ρ+ cells exposed to Aβ1-42 we observed a decrease 
in COX activity and lower ATP content. Aβ-induced metabolic dysfunction has been 
largely demonstrated. PC12 cells treated with increasing concentrations of Aβ peptides 
had mitochondrial alterations where complex I, II, III and IV deficits were evident 
(Pereira et al., 1999). Indeed, it was verified an impairment of glycolysis resulting in 
ATP depletion (Pereira et al., 1999). Although the exact mechanism by which Aβ 
induces cell death is not yet fully clarified, there is evidence that this peptide, added 
extracelullary, can act intracelullary, increasing mitochondrial dysfunction (Hansson 
Petersen et al., 2008), lowering antioxidant enzymatic activity, and increasing oxidative 
stress. Aβ treatments in mtDNA depleted NT2 cells that do not contain functional ETC, 
 could not exert cytotoxicity. This study was the ultimate evidence of the link between 
Aβ-mediated toxicity and mitochondrial dysfunction (Cardoso et al., 2001; Cardoso et 
al., 2009). Accordingly it was observed that Aβ species were associated with human AD 
brain mitochondria (Hirai et al., 2001; Caspersen et al., 2005; Devi et al., 2006; 
Manczak et al., 2006). Further, mitochondria isolated from human AD frontal cortex 
show inefficient MRC within dystrophic neurites, associated with Aβ peptides 
deposition in these regions (Perez-Gracia et al., 2008). The described effects of Aβ 
peptides targeted to mitochondria include failure in ETC enzymes namely COX and 
inhibition of ATP production (reviewed in Reddy and Beal), as our results also indicate. 
Our results and others point to the possibility that mitochondrial abnormalities start a 
sequence of cellular events that give rise to AD pathogenesis. Since we had established 
that Aβ1-42 induced mitochondrial dysfunction we moved forward in order to tackle the 
connection between this event and the major AD pathological hallmarks: Aβ 
oligomerization and deposition ,and Tau hyperphosphorylation.  
Given that microtubule dynamics is dependent on the availability of ATP we 
hypothesize about the importance of microtubule disassembly in AD. Evidence from 
pyramidal neurons from AD patients brain showed microtubule alterations concomitant 
with mitochondrial abnormalities before detectable NFT (Cash et al., 2003).  
Tau protein as a neuronal microtubule associated protein (MAP) is important for 
microtubules proper function, neurite growth and maintenance (Stamer et al., 2002). It 
was demonstrated that overexpression of Tau results in a change in cellular shape, loss 
of polarization and delayed cell growth. In addition, mitochondrial distribution was 
profoundly altered becoming preferentially localized near the microtubule organization 
centre (MTOC) with a clustering aspect (Ebneth et al., 1998). Evidence from Tau 
overexpressing cells supports the referred idea, where transport along microtubules was 
 inhibited and this effect was prominent in the plus-end direction (Stamer et al., 2002; 
Mandelkow et al., 2003). Moreover, these cells have shorter neurites and showed to be 
more sensitive to oxidative stress, since the lower amount of mitochondria in cellular 
processes implies less bioenergetics leading to the retrograde degeneration or “dyeing 
back” phenomenon (Mandelkow et al., 2003). More recently, Guo and colleagues 
(2006) demonstrated that Aβ binds to Tau in solution, suggesting that this may be the 
precursor event to latter aggregation of both molecules. This binding enhances Tau 
phosphorylation which can form aggregates that may block the intracellular traffick, 
including AVs to lysosomes movement (Guo et al., 2006). In our model Aβ exposure 
triggered an increase in Tau hyperphosphorilation which was reverted by taxol. 
Nocodazole exposure could slightly enhance Tau hyperphosphorylation which made us 
hypothesize that, even in the presence of Aβ, if microtubules are stabilized Tau may not 
be dissociated from microtubules avoiding its availability to kinases that promote 
hyperphosphorylation. 
Moreover, results obtained in SHSY-5Y cells, where Aβ-driven bioenergetics failure 
resulted in increased free tubulin levels. Besides free tubulin increase we have also 
found reduced levels of acetylated tubulin when cells were treated with Aβ1-42. Tubulin 
acetylation is a reliable indicator of microtubule stability and has been found reduced in 
AD (Hempen and Brion, 1996). We associated lower levels of acetylated tubulin to 
higher NAD+/NADH ratio observed under the same conditions. The bridge between 
these two events may be the activation of SIRT2, a cytoplasmic deacetylase known to 
have tubulin as a preferential substrate (North et al., 2003) which is dependent on the 
availability of NAD+ for enzymatic activity. Because SIRT2 expression is not an 
indicator of its activation we access this enzyme activity indirectly by determining 
tubulin acetylation. Recent data from Henriques and colleagues (2010) showed in 
 primary neuronal cultures exposed to Aβ, tubulin cytoskeleton abnormalities, including 
reduced levels of acetylated tubulin, which impaired vesicular anterograde transport. 
Our microtubule alterations were reversed by taxol treatments indicating that 
microtubule network disruption are implicated in Aβ-induced citotoxicity. Microtubule 
disturbance may lead to an impairment of the autophagic pathway, since AVs are 
transport through microtubules (Cuervo, 2004). Evidence from AD brains showing 
massive AVs accumulation within dystrophic neurites (Nixon et al., 2005; Yu et al., 
2005) suggested that autophagy is simultaneously impaired and induced in AD. Given 
that AVs in the brain are the major source of intracellular Aβ (Yu et al., 2005) an 
impairment of autophagic pathway compromise its normal clearance favoring Aβ 
oligomers production. Hung and co-workers (2009) found that Aβ peptides could 
activate autophagy increasing autophagosome formation and LC3II levels in SH-
SY5Y/pEGFP-LC3 cell line. In accordance, we showed that Aβ is able to augment 
LC3II levels and that this effect could be partially reversed by taxol pretreatment. 
Moreover, experiences performed with vinblastine, an inhibitor of microtubule 
assembly during a period of few hours, caused the accumulation of AVs in neurites 
(Boland et al., 2008). Furthermore, Beclin-1 is required for autophagy induction in vivo, 
and it was reported that the levels of mRNA of this protein are reduced in subjects with 
middle cognitive impairment (MCI) and severe AD (Lee & Gao, 2008). Indeed, this 
reduction in Beclin-1 is associated with enhancement in Aβ pathology in APP mice 
model and the possible explanation is reduced autophagy. Interestingly, we do not see 
alterations induced by Aβ in Beclin-1 expression.  
Yang and colleagues has reported that activated caspase 3 was found within dystrophic 
neurites, most exactly in AVs associated with amyloid plaques in PS/APP mice (Yang 
et al., 2008). Pro-apoptotic proteins will accumulate and apoptotic cell death can take 
 place culminating in neurodegeneration observed in AD brains. This imbalance between 
AVs formation and degradation verified in AD, drives cells into a so called “autophagic 
stress” (Chu, 2006). Clearance of AVs requires intact microtubules, so that they can go 
towards the cell body where the lysosomes are located (Nixon, 2007). In fact, taxol 
revealed efficacy in reducing Aβ insoluble oligomers which we attribute to microtubule 
dependent autophagy improvement. Autophagy acquires a protective role since Aβ 
oligomers are cleared and apoptotic cell death is attenuated in our cellular model. Our 
results point to a decrease in caspase 9 and 3 activation with taxol. 
Indeed, it was observed an increase in mitochondrial degradation products in vulnerable 
AD neurons, suggesting an augmented mitochondrial turn-over by mitophagy (Moreira 
et al., 2007). The results obtained from our experiments show that taxol treatment can 
revert the loss of mitochondrial membrane potential and normalize NAD+/NADH ratios. 
We hypothesize that Aβ are being targeted to mitochondria and arrested by TOM 40, 
one of the mitochondrial translocase proteins (Anandatheerthavarada et al., 2003). Then, 
the transport towards the inner membrane is assured by the translocase of the inner 
membrane (TIM) (Hansson Petersen et al., 2008).  
Accordingly with our results, Aβ was also found within mitochondrial membrane, 
inducing COX dysfunction and lowering of ATP levels in transfected PC12 cells with 
APPwt and APPsw (Keil et al., 2004). Interestingly, Aβ oligomers in mitochondrial 
fractions where also lowered upon taxol exposure. These data prove that by restoring 
microtubule network, Aβ-damaged mitochondria are degraded by macroautophagy, 
giving further support to the idea that mitophagy is a prominent feature in AD.  
Data from SHSY-5Y ρ0 cells show that these cells can maintain ∆Ψm and ATP levels 
similar to SHSY-5Y ρ+ cells despite the depletion of their mtDNA. This fact arise from  
 a “reversal” of ATP synthase activity, where nuclear encoded ATP synthase subunits 
assemble and maintain proton gradient across mitochondrial membrane (Nijlmans et al., 
1995, Cardoso et al., 2001). Since these cells can maintain ATP levels microtubule 
breakdown could be prevented. Nevertheless, we found low levels of acetylated tubulin 
followed by huge increase in NAD+ which indicated SIRT2 activation. As discussed 
before acetylation alteration induces microtubule instability, which can correlate with 
Tau hyperphosphorilation augmented levels. Taxol could prevent these alterations. Such 
data further support our idea that mitochondrial dysfunction is correlated with ALP 
alteration through microtubule network impairment.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 5 
Final remarks 
 
 
 
 AD and other neurodegenerative disorders are expected to constitute a major health 
problem as life expectancy boost. Efforts have been taken in order to tackle innovate 
therapies namely, addressing mitochondrial dysfunction, a striking feature in AD, that 
has great influence in the etiology of the disease. The outcomes of mitochondrial 
abnormal metabolism: lower ATP levels, ROS overproduction; may deregulate many 
cellular processes, for instance, SIRT2 activation and consequent tubulin deacetylation 
may be implicated in microtubule network integrity. Upon microtubule network 
disruption axonal transport becomes compromised and the accumulation of autophagic 
vesicles in dystrophic neurites is prominent. The γ-secretase complex, described to be 
present in AVs membranes, cleaves APP leading to a major production of Aβ peptides. 
The increased accumulation of Aβ peptides results from the lack of fusion between AVs 
and lysosomes. Cytosolic Aβ may be then imported into the mitochondria where exerts 
further toxicity. A feedback mechanism becomes established where the impaired 
autophagic pathway results in a burden of Aβ peptides production which worsen 
mitochondrial dysfunction (Figure19).  
 ratio
 
 
Fig.19. Positive feedback mechanism in AD etiogenesis. 
Mitochondrial dysfunction is the leading step in the molecular 
mechanisms underlying aged-related AD. The consequent 
bioenergetics failure leads to microtubule network breakdown 
impeding AVs retrograde transport to occur and lysosomal fusion. The 
impairment in autophagic pathway favors the accumulation of toxic 
protein oligomers (Aβ) and dysfunctional mitochondria which 
culminates in the neurodegeneration pathway observed in AD brains. 
 
Data presented in this thesis show that Aβ1-42 added extracellulary induce mitochondrial 
dysfunction by lowering ATP levels, decreasing in COX activity and increasing 
 NAD+/NADH ratios. These events drive microtubule destabilization interfering with 
proper dynamic of this structure. Microtubule dynamics is compromised in two 
different ways: (1) ATP levels decrease the capacity of polymerization that culminated 
in augmented free tubulin ratios; (2) SIRT2 is activated in consequence to NAD+ 
increased availability, deacetylates tubulin and promotes further microtubule instability. 
Given that tubulin cytoskeleton is no longer efficient, AVs retrograde transport is 
impeded and accumulates within cell. The absence of proper clearance of degradative 
products favors Aβ oligomerization and deposition which activates mitochondrial 
dependent apoptotic cell death.  
These observations indicated us that microtubule stabilizers could ameliorate Aβ-
dependent microtubule damage. In fact we proved that pretreatment with taxol was 
efficient recuing cells from augmented free tubulin and tubulin deacetylation. Moreover 
Tau hyperphosphorylation caused by Aβ–mediated mitochondrial damage was 
decreased upon taxol exposure. Since microtubule integrity is restored upon taxol 
treatment Aβ oligomerization and deposition was partially reverted, in accordance with 
a decrease in caspase activation. Autophagy is likely to be implied in this process 
because LC3II levels partially decreased with taxol treatment, indicating that a 
functional microtubule network allows AVs to fuse with lysosomes. Interestingly, the 
presence of taxol decreased mitochondrial Aβ oligomers content, protected against 
mitochondrial rhodamine retention loss and decreased NAD+ augmented levels. These 
results show that restored microtubule integrity enabled dysfunctional mitochondria to 
be degraded by mitophagy. 
Although, taxol cannot cross the blood brain barrier, our data point to a microtubule 
targeted therapy in AD. Currently, in our laboratory we are testing the effects of NAP, a 
targeted microtubule peptide that act at a microtubule level. NAP passed the toxicity 
 tests and is now being tested in AD patients in phase II clinical trials. It will be 
interesting to address in our models whether this peptide improves cell viability.  
Overall, we propose a new therapeutic target: microtubules, as a reliable future 
restorative strategy in AD, since they are likely to be perturbed early in the disease 
progression. This approach allows for an intervention up-stream in the events leading to 
AD pathogenesis. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
References  
 
 
 
 Aliev G., Palacios H.H., Walrafen B., Lipsitt A.E., Obrenovich M.E. & L. Morales 
(2009). Brain mitochondria as a primary target in the development of treatment 
strategies for Alzheimer disease. Int J Biochem Cell Biol 41:1989-2004. 
Anandatheerthavarada H.K., Biswas G., Robin M.A. & N.G. Avadhani (2003). 
Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's 
amyloid precursor protein impairs mitochondrial function in neuronal cells. J 
Cell Biol 161:41-54. 
Balaban R.S,. Nemoto S. & T. Finkel (2005). Mitochondria, oxidants, and aging. Cell 
25 120:483-95. 
Barsoum M.J., Yuan H., Gerencser A.A., Liot G., Kushnareva Y., Gräber S., Kovacs I., 
Lee W.D., Waggoner J., Cui J., White A.D., Bossy B., Martinou J.C., Youle 
R.J., Lipton S.A., Ellisman M.H., Perkins G.A. & E. Bossy-Wetzel (2006). 
Nitric oxide-induced mitochondrial fission is regulated by dynamin-related 
GTPases in neurons. EMBO J 25:3900-11. 
Beal M.F. (2005). Mitochondria take center stage in aging and neurodegeneration. Ann 
Neurol 58:495-505. 
Belinson H. & D.M. Michaelson (2009) ApoE4-dependent Abeta-mediated 
neurodegeneration is associated with inflammatory activation in the 
hippocampus but not the septum. J Neural Transm 116:1427-34. 
Boland B., Kumar A., Lee S., Platt F.M., Wegiel J. , Yu W.H. & R.A. Nixon (2008). 
Autophagy Induction and Autophagosome Clearance in Neurons: Relationship 
to Autophagic Pathology in Alzheimer's Disease. J Neurosci 28:6926–6937. 
Bosetti F., Brizzi F., Barogi S., Mancuso M., Siciliano G., Tendi E.A., Murri L., 
Rapoport S.I. & Solaini G (2002). Cytochrome c oxidase and mitochondrial 
 F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with 
Alzheimer's disease. Neurobiol Aging 23:371 -6. 
Boumezbeur F., Mason G.F., de Graaf R.A., Behar K.L., Cline G.W., Shulman G.I, 
Rothman DL. & K.F. Petersen (2010). Altered brain mitochondrial metabolism 
in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J 
Cereb Blood Flow Metab 30:211-21. 
Brewer G.J. (2000). Neuronal plasticity and stressor toxicity during aging. Exp Gerontol 
35:1165-83.  
Bu G. (2009). Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, 
pathogenesis and therapy. Nat Rev Neurosci 10:333-44. 
Butler D., Bendiske J., Michaelis M.L., Karanian D.A. & B.A. Bahr (2007). 
Microtubule-stabilizing agent prevents protein accumulation-induced loss of 
synaptic markers. Eur J Pharmacol 562:20-7. 
Butterfield D.A. & C.M. Lauderback (2002). Lipid peroxidation and protein oxidation in 
Alzheimer's disease brain: potential causes and consequences involving amyloid 
beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 
32:1050-60. 
Cacabelos R., Fernandez-Novoa L., Lombardi V., Kubota Y. & M. Takeda (2005). 
Molecular genetics of Alzheimer's disease and aging. Methods Find Exp Clin 
Pharmacol 27:1-573. 
Cappelletti G., Surrey T. & R. Maci (2005). The parkinsonism producing neurotoxin 
MPP+ affects microtubule dynamics by acting as a destabilising factor. FEBS 
Lett 579:4781–4786. 
 Cardoso S.M., Pereira C.F., Moreira P.I., Arduino D.M., Esteves A.R. & C.R. Oliveira 
(2009).  Mitochondrial control of autophagic lysosomal pathway in Alzheimer's 
disease. Exp Neurol 223:294-8.  
Cardoso S.M., Proença M.T., Santos S., Santana I. & C.R Oliveira. (2004) Cytochrome 
c oxidase is decreased in Alzheimer’s disease platelets. Neurobiol Aging 25: 
105–110. 
Cardoso S.M., Santos S., Swerdlow R.H. & C.R. Oliveira (2001). Functional 
mitochondria are required for amyloid β-mediated neurotoxicity. FASEB J 
15:1439-1441. 
Cardoso S.M., Swerdlow R.H. & C.R. Oliveira (2002) Induction of cytocrome c-
mediated apoptosis by amyloid beta 25-35 requires functional mitochondria. 
Brain Res 931(2): 117-125. 
Cash A.D., Aliev G., Siedlak S.L., Nunomura A., Fujioka H., Zhu X, Raina A.K., 
Vinters H.V., Tabaton M., Johnson A.B., Paula-Barbosa M., Avíla J., Jones 
P.K., Castellani R.J., Smith M.A. & G.Perry. Microtubule reduction in 
Alzheimer's disease and aging is independent of Tau filament formation. Am J 
Pathol 162:1623-7 (2003). 
Casley C.S., Canevari L., Land J.M., Clark J.B. & M.A. Sharpe (2002). β-Amyloid 
inhibits integrated mitochondrial respiration and key enzyme activities. J 
Neurochem 80:91-100. 
Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J.W., Xu H.W., Stern 
D., McKhann G. & S.D. Yan (2005). Mitochondrial Abeta: a potential focal 
point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 
19:2040-1. 
 Cataldo A.M., Hamilton D.J., Barnett J.L., Paskevich P.A. & R.A. Nixon (1996).   
Abnormalities of the endosomal-lysosomal system in Alzheimer's disease: 
relationship to disease pathogenesis. Adv Exp Med Biol 389:271-80. 
Chan D.C. (2006). Mitochondria: dynamic organelles in disease, aging, and 
development. Cell 125:1241-52. 
Chen J.X. & S.D. Yan (2007). Amyloid-β-Induced Mitochondrial Dysfunction. J 
Alzheimers Dis 12:177-84. 
Chen Y., Hill S., Faibushevich A. &  M.L. Michaelis (2001). Effects of Taxol on Aβ-
induced activation of caspase-8 in primary neurons. Soc Neurosci Abstr 27, 
963.1. 
Cho D.H., Nakamura T., Fang J., Cieplak P., Godzik A., Gu Z. & S.A. Lipton (2009). 
S-Nitrosylation of Drp1 Mediates b-Amyloid–Related Mitochondrial Fission 
and Neuronal Injury. Science 324:102-5. 
Chong Z.Z., Lin S.H., Li F. & K. Maiese (2005). The sirtuin inhibitor nicotinamide 
enhances neuronal cell survival during acute anoxic injury through AKT, BAD, 
PARP, and mitochondrial associated "anti-apoptotic" pathways. Curr Neurovasc 
Res 2:271-85. 
Chu C.T. (2006). Autophagic stress in neuronal injury and disease. J Neuropathol Exp  
Cortopassi G.A. & A. Wong (1999). Mitochondria in organismal aging and 
degeneration. Biochim Biophys Acta 1410:183-93. 
Cregan, S.P., MacLaurin, J.G., Craig, C.G., Robertson, G.S., Nicholson, D.W., Park, 
D.S. & R.S. Slack (1999). Bax-dependent caspase-3 activation is a key 
determinant in p53-induced apoptosis in neurons. J.Neurosci. 19, 7860–7869. 
Cuervo A.M. (2004). Autophagy: many paths to the same end. Mol Cell Biochem 
263:55–72. 
 Cummings JL. & G. Cole (2002). Alzheimer disease. JAMA 287:2335-8. 
Denu J.M. (2005). The Sir 2 family of protein deacetylases. Curr Opin Chem Biol 
9:431-40. 
Devi L., Prabhu B.M., Galati D.F., Avadhani N.G. & H.K. Anandatheerthavarada 
(2006). Accumulation of amyloid precursor protein in the mitochondrial import 
channels of human Alzheimer's disease brain is associated with mitochondrial 
dysfunction. J Neurosci 26:9057-68. 
Divinski I., Holtser-Cochav M., Vulih-Schultzman I., Steingart R.A. & I. Gozes (2006). 
Peptide neuroprotection through specific interaction with brain tubulin. J 
Neurochem 98:973-84.  
Divinski I., Mittelman L. & I. Gozes (2004). A femtomolar acting octapeptide interacts 
with tubulin and protects astrocytes against zinc intoxication. J Biol Chem 
279:28531-8. 
Duchen M.R. (2004). Mitochondria in health and disease: perspectives on a new 
mitochondrial biology. Mol Aspects Med 25: 365-45. 
Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B. & E. Mandelkow 
(1998). Overexpression of Tau protein inhibits kinesin-dependent trafficking of 
vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's 
disease. J Cell Biol 143:777-94. 
Evin G, Zhu A, Holsinger R.M., Masters C.L. & Q.X. (2003). Li Proteolytic processing 
of the Alzheimer's disease amyloid precursor protein in brain and platelets. J 
Neurosci Res 74:386-92. 
 Ferreiro E., Resende R., Costa R., Oliveira C.R. & C.M. (2006). Pereira An 
endoplasmic-reticulum-specific apoptotic pathway is involved in prion and 
amyloid-beta peptides neurotoxicity. Neurobiol Dis 23:669-78. 
Fukui H. & C.T Moraes (2008). The mitochondrial impairment, oxidative stress and 
neurodegeneration connection: reality or just an attractive hypothesis? Trends 
Neurosci 31:251-6. 
Gong C.X. & K. Iqbal (2008). Hyperphosphorylation of Microtubule-Associated 
Protein Tau: A Promising Therapeutic Target for Alzheimer Disease. Curr Med 
Chem 15: 2321–2328. 
Götz J., Ittner L.M., Schonrock N. & R. Cappai (2008). An update on the toxicity of Aβ 
in Alzheimer’s disease. Neuropsychiatr Dis Treat 4:1033–1042. 
Götz J., Schild A., Hoerndli F. & L. Pennanen (2004). Amyloid-induced neurofibrillary 
tangle formation in Alzheimer's disease: insight from transgenic mouse and 
tissue-culture models. Int J Dev Neurosci 22:453-65. 
Gozes I. & I. Divinski (2004). The femtomolar-acting NAP interacts with microtubules: 
Novel aspects of astrocyte protection. J Alzheimers Dis 6:37-41. 
Gozes I., Divinski I. & I. Piltzer (2008). NAP and D-SAL: neuroprotection against the 
beta amyloid peptide (1-42). BMC Neurosci 9 Suppl 3:S3. 
Gozes I., Morimoto B.H., Tiong J., Fox A., Sutherland K., Dangoor D., Dangoor D., 
Holser-Cochav M., Vered K., Newton P., Aisen P.S., Matsuoka Y., van Dyck 
C.H. & L.Thal (2005). NAP: research and development of a peptide derived 
from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 
11:353-68. 
 Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S, Thompson L.M. & 
F.M. LaFerla (2008). Nicotinamide restores cognition in Alzheimer's disease 
transgenic mice via a mechanism involving sirtuin inhibition and selective 
reduction of Thr231-phosphoTau. J Neurosci 28:11500-10 (2008). 
Guo J.P., Arai T., Miklossy J. & P.L. McGeer (2006). Aβ and Tau form soluble 
complexes that may promote self aggregation of both into the insoluble forms 
observed in Alzheimer’s disease. Proc Natl Acad Sci U S A 103:1953-8. 
Han S.H. (2009). Potential role of sirtuin as a therapeutic target for neurodegenerative 
diseases. J Clin Neurol 5:120-5. 
Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, 
Leinonen V., Ito A., Winblad B., Glaser E. & M. Ankarcrona (2008). The 
amyloid betapeptide is imported into mitochondria via the TOM import 
machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. U. S. A. 
105:13145–13150. 
Hardy J. & D.J. Selkoe (2002). The amyloid hypothesis of Alzheimer's disease: 
progress and problems on the road to therapeutics. Science 297, 353-356. 
Hempen, B. & J.P Brion (1996). Reduction of acetylated α-tubulin immunoreactivity in 
neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. 
Exp. Neurol. 55, 964–972. 
Henriques A.G., Vieira S.I., da Cruz E Silva E.F. & A.O. da Cruz E Silva (2010). Abeta 
promotes Alzheimer's disease-like cytoskeleton abnormalities with 
consequences to APP processing in neurons. J Neurochem. 113(3):761-71. 
Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R., Atwood C.S., Johnson A.B., 
Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., 
 Harris P.L., Jones P.K., Petersen R.B., Perry G. & M.A. Smith (2001). 
Mitochondrial Abnormalities in Alzheimer’s Disease. J Neurosci 21:3017–3023. 
Howell N., Elson J.L., Chinnery P.F. & D.M. Turnbull (2005). mtDNA mutations and 
common neurodegenerative disorders. Trends Genet 21:583-6. 
Hung S.Y., Huang W.P., Liou H.C. & W.M. Fu (2009). Autophagy protects neuron 
from Abeta-induced cytotoxicity. Autophagy. 5(4):502-10. 
Iqbal K., and I. Grundke-Iqbal (2008). Alzheimer neurofibrillary degeneration: 
significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 
12:38-55. 
Joshi, H. C. & D. W. Cleveland (1989). Differential utilization of β-tubulin isotypes in 
differentiating neurites. J. Cell Biol. 109, 663–673. 
Julien C., Tremblay C., Emond V., Lebbadi M., Salem N Jr., Bennett D.A. & F. Calon 
(2009). Sirtuin 1 reduction parallels the accumulation of Tau in Alzheimer 
disease. J Neuropathol Exp Neurol 68:48-58. 
Keil U, Bonert A, Marques CA, Scherping I, Weyermann J, Strosznajder JB, Müller-
Spahn F, Haass C., Czech C., Pradier L., Müller W.E. & A. Eckert (2004). 
Amyloid beta-induced changes in nitric oxide production and mitochondrial 
activity lead to apoptosis. J Biol Chem 279:50310-20. 
King M.P. & G. Attardi (1989). Human cells lacking mtDNA: repopulation with 
exogenous mitochondria by complementation. Science 246:500-3. 
Klafki H.W., Wiltfang J. & M. STaufenbiel (1996). Electrophoretic separation of βA4 
peptides (1-40) and (1-42). Anal Biochem 237:24–29. 
Klionsky D.J., Elazar Z., Seglen P.O. & D.C. Rubinsztein (2008). Does bafilomycin A1 
block the fusion of autophagosomes with lysosomes? Autophagy 4:849–950. 
 Kochl R., Hu X.W., Chan E.Y. & S.A. Tooze (2006). Microtubules facilitate 
autophagosome formation and fusion of autophagosomes with endosomes. 
Traffic 7:129–145. 
Laws S.M., Hone E., Gandy S. & R.N. Martins (2003). Expanding the association 
between the APOE gene and the risk of Alzheimer's disease: possible roles for 
APOE promoter polymorphisms and alterations in APOE transcription. J 
Neurochem 84:1215-36. 
Lee J.A. & F.B. Gao (2008). Regulation of Abeta pathology by beclin 1: a protective 
role for autophagy? J Clin Invest 118:2015-8. 
Lee V. M., Daughenbaugh R., & J.Q. Trojanowski (1994). Microtubule stabilizing 
drugs for the treatment of Alzheimer’s disease. Neurobiol Aging 2:87–89. 
Levine B. & G. Kroemer (2008). Autophagy in the pathogenesis of disease. Cell 
132:27-42. 
Li B., Chohan M.O., Grundke-Iqbal I. & K. Iqbal (2007).  Disruption of microtubule 
network by Alzheimer abnormally hyperphosphorylated Tau. Acta Neuropathol 
113:501-11. 
Li G., Faibushevich A., Turunen B.J., Yoon S.O., Georg G., Michaelis M.L. & R.T. 
Dobrowsky (2003). Stabilization of the cyclin-dependent kinase 5 activator, p35, 
by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J Neurochem 
84:347-62. 
Lin M.T. & Beal M.F. (2006). Mitochondrial dysfunction and oxidative stress in 
neurodegenerative diseases. Nature 443:787-95. 
Liu Y, Ali S.M., Boge T.C., Georg G.I., Victory S., Zygmunt J. Marquez R.T. & R.H. 
Himes (2002). A systematic SAR study of C10 modified paclitaxel analogues 
using a combinatorial approach. Comb Chem High Throughput Screen 5:39-48. 
 Maas T., Eidenmüller J. & R. Brandt (2000). Interaction of Tau with the neural 
membrane cortex is regulated by phosphorylation at sites that are modified in 
paired helical filaments. J Biol Chem 275:15733-40. 
Maccioni R.B., Muñoz J.P. & L. Barbeito (2001). The molecular bases of Alzheimer's 
disease and other neurodegenerative disorders. Arch Med Res 32(5):367-81. 
Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., & P.H. Reddy (2006). 
Mitochondria are a direct site of Abeta accumulation in Alzheimer's disease 
neurons: implications for free radical generation and oxidative damage in 
disease progression. Hum Mol Genet 15:1437-1449. 
Manczak M., Park B.S., Jung Y. & P.H. Reddy (2004). Differential expression of 
oxidative phosphorylation genes in patients with Alzheimer's disease: 
implications for early mitochondrial dysfunction and oxidative damage. 
Neuromolecular Med 5:147-62. 
Mandelkow E.M., Stamer K., Vogel R., Thies E. & E. Mandelkow (2003). Clogging of 
axons by Tau, inhibition of axonal traffic and starvation of synapses. Neurobiol 
Aging 24:1079-85.  
Marlow L., Cain M., Pappolla M.A. & K. Sambamurti (2003). Beta-secretase 
processing of the Alzheimer's amyloid protein precursor (APP). J Mol Neurosci 
20:233-9. 
Matsuoka Y, Gray A.J., Hirata-Fukae C., Minami S.S., Waterhouse E.G., Mattson M.P. 
LaFerla F.M., Gozes I. & P.S. Aisen (2007). Intranasal NAP administration 
reduces accumulation of amyloid peptide and Tau hyperphosphorylation in a 
transgenic mouse model of Alzheimer's disease at early pathological stage. J 
Mol Neurosci 31:165-70. 
 Matsuoka Y., Jouroukhin Y., Gray A.J., Ma L., Hirata-Fukae C., Li H.F., Feng L., 
Lecanu L., Walker B.R., Planel E., Arancio O., Gozes I. & P.S. Aisen (2008). A 
neuronal microtubule-interacting agent, NAPVSIPQ, reduces Tau pathology and 
enhances cognitive function in a mouse model of Alzheimer's disease. J 
Pharmacol Exp Ther 325:146–153. 
Mattson M.P. (2000). Existing data suggest that Alzheimer's disease is preventable. Ann 
N Y Acad Sci   924:153-9.  
Mattson M.P. (2004). Pathways towards and away from Alzheimer´s disease. Nature 
430:631-9. 
Michaelis M.L. (2003). Drugs targeting Alzheimer's disease: some things old and some 
things new. J Pharmacol Exp Ther 304:897-904.  
Michaelis M.L., Ansar S., Chen Y., Reiff E.R., Seyb K.I., Himes R.H., Audus K.L. & 
GI. Georg (2005). {beta}-Amyloid-induced neurodegeneration and protection by 
structurally diverse microtubule-stabilizing agents. J Pharmacol Exp Ther 
312:659-68. 
Michaelis M.L., Dobrowsky R.T. & G. Li (2002). Tau neurofibrillary pathology and 
microtubule stability. J Mol Neurosci 19:289-93. 
Michan S. & D. Sinclair (2007). Sirtuins in mammals: insights into their biological 
function. Biochem J 404:1-13.   
Migliore L., Fontana I., Trippi F., Colognato R., Coppedè F., Tognoni G., Nucciarone 
B. & G. Siciliano (2005). Oxidative DNA damage in peripheral leukocytes of 
mild cognitive impairment and AD patients. Neurobiol Aging 26:567-73. 
Mizushima N. (2005). Aβ generation in autophagic vacuoles. J Cell Biol 171:15-7. 
 Moreira P.I., Siedlak S.L., Wang X., Santos M.S., Oliveira C.R., Tabaton M., 
Nunomura A., Szweda L.I., Aliev G., Smith M.A., Zhu X. & G. Perry 
(2007).Autophagocytosis of Mitochondria Is Prominent in Alzheimer Disease. J 
Neuropathol Exp Neurol 66:525-532. 
Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H. & L. Berg 
(2001). Mild cognitive impairment represents early-stage Alzheimer disease. 
Arch Neurol 58:397-405. 
Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 
55–63. 
Murphy M.P. (2009). How mitochondria produce reactive oxygen species. Biochem J 
Vol. 417, 1-13.  
Nakagawa T., Zhu H., Morishima N., Li E., Xu J. & B.A. Yankner (2000). Caspase-12 
mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-
beta. Nature 403:98-103. 
Neurol; 65(5):423-32. 
Neve R.L, McPhie D.L. & Y. Chen (2000). Alzheimer's disease: a dysfunction of the 
amyloid precursor protein. Brain Res 886:54-66. 
Nijlmans L.G.J., Spelbrink J.N., Van Galen M.J.M, Zwaan M., Klement P. & C. 
Vanden Bogert (1995) Biochem. Biophys. Act 1265, 117–126. 
Nixon R.A. (2007). Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci 
120:4081-4091. 
 Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A. & A.M. Cuervo 
(2005). Extensive involvement of autophagy in Alzheimer disease: an immuno-
electron microscopy study. J Neuropathol Exp Neurol 64:113-22. 
North B.J., Marshall B.L., Borra M.T., Denu J.M. & E. Verdin (2003). The human Sir2 
ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11:437-
44. 
Onyango I.G., Tuttle J.B. & J.P. Jr. Bennett (2005). Altered intracellular signaling and 
reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-
amyloid peptide acting through receptor for advanced glycation end products 
(RAGE). Mol Cell Neurosci 29:333-43. 
Outeiro T.F., Marques O. & A. Kazantsev (2008). Therapeutic role of sirtuins in 
neurodegenerative disease. Biochim Biophys Acta 1782:363-9. 
Outeiro,T.F., Kontopoulos E., Altmann S. M., Kufareva I., Strathearn K. E., Amore 
A.M., Volk C.B., Maxwell M.M., Rochet J.C., McLean P.J., Young A.B., 
Abagyan R., Feany M.B., Hyman B.T. & A.G. Kazantsev (2007). Sirtuin 2 
Inhibitors Rescue a-Synuclein–Mediated Toxicity in Models of Parkinson’s 
Disease. Science 317(5837):516-9. 
 
Padurariu M., Ciobica A., Hritcu L., Stoica B., Bild W. & C. Stefanescu (2010). 
Changes of some oxidative stress markers in the serum of patients with mild 
cognitive impairment and Alzheimer's disease. Neurosci Lett 469:6-10. 
Parihar M.S., Kunz E.A. & G.J. Brewer (2008). Age-related decreases in NAD(P)H and 
glutathione cause redox declines before ATP loss during glutamate treatment of 
hippocampal neurons. J Neurosci Res 86:2339-52. 
 Pereira C. Agostinho P., Moreira PI., Cardoso S.M. & C.R. Oliveira (2005). 
Alzheimer’s Disease-Associated Neurotoxic Mechanisms and Neuroprotective 
Strategies. Curr Drug Targets CNS Neurol Disord 4:383-403.  
Pereira C., Santos M.S. & C. Oliveira (1999). Involvement of Oxidative Stress on the 
Impairment of Energy Metabolism Induced by Aβ Peptides on PC12 Cells: 
Protection by Antioxidants. Neurobiol Dis 6:209-19. 
Perez-Gracia E., Torrejon-Escribano B. & I. Ferrer, (2008). Dystrophic neurites of 
senile plaques in Alzheimer's disease are deficient in cytochrome c oxidase. 
Acta Neuropathol 116, 261-268. 
Pocernich C.B. & D.A. Butterfield (2003). Acrolein inhibits NADH-linked 
mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox 
Res 5:515-20. 
Raber J., Huang Y. & J.W. Ashford (2004). ApoE genotype accounts for the vast 
majority of AD risk and AD pathology. Neurobiol Aging 25:641-50. 
Reddy P.H. & S. McWeeney (2006). Mapping cellular transcriptosomes in autopsied 
Alzheimer's disease subjects and relevant animal models. Neurobiol Aging 
27:1060-77. 
Resende R., Ferreiro E., Pereira C. & C.R. Oliveira (2008). Neurotoxic effect of 
oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of 
endoplasmic reticulum calcium release in oligomer-induced cell death. 
Neuroscience. 155(3):725-37. 
Ross C.A. & M.A. Poirier (2005). Opinion: What is the role of protein aggregation in 
neurodegeneration? Nat Rev Mol Cell Biol 6(11):891-8. 
 Sambamurti K., Greig N.H. & D.K. Lahiri (2002). Advances in the cellular and 
molecular biology of the beta-amyloid protein in Alzheimer's disease. 
Neuromolecular Med  1:1-31. 
Santa-María I., Smith M.A., Perry G., Hernández F., Avila J. & F.J. Moreno (2005). 
Effect of quinones on microtubule polymerization: a link between oxidative 
stress and cytoskeletal alterations in Alzheimer's disease. Biochim Biophys Acta 
1740:472-80. 
Selkoe D.J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 
81:741-66. 
Seyb K.I, Ansar S., Bean J. & M.L. Michaelis (2006). Beta-Amyloid and endoplasmic 
reticulum stress responses in primary neurons: effects of drugs that interact with 
the cytoskeleton. J Mol Neurosci 28:111-23. 
Shepherded C., McCann H. & G.M. Halliday (2009). Variations in the neuropathology 
of familial Alzheimer’s disease. Acta Neuropathol 118:37-52.  
Shi C., Guo K., Yew D.T., Yao Z., Forster E.L., Wang H. & J. Xu (2008). Effects of 
ageing and Alzheimer's disease on mitochondrial function of human platelets. 
Exp Gerontol 43:589-94. 
Shigenaga M.K., Hagen T.M. & B.N. Ames (1994). Oxidative damage and 
mitochondrial decay in aging. Proc Natl Acad Sci U S A 8; 91:10771-8. 
Shiryaev N., Jouroukhin Y., Giladi E., Polyzoidou E., Grigoriadis NC., Rosenmann H. 
& I. Gozes. NAP protects memory, increases soluble Tau and reduces Tau 
hyperphosphorylation in a Tauopathy model. Neurobiol Dis 34:381-8 (2009). 
Small S.A. & K. Duff (2008). Linking Abeta and Tau in late-onset Alzheimer's disease: 
a dual pathway hypothesis. Neuron 60:534-42. 
 Sorrentino G. & V. Bonavita (2007). Neurodegeneration and Alzheimer's disease: the 
lesson from Tauopathies. Neurol Sci 28:63-71. 
Stamer K., Vogel R., Thies E., Mandelkow E. & E.M. Mandelkow (2002). Tau blocks 
traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances 
oxidative stress. J Cell Biol 156:1051-63. 
Stocchi V., Cucchiarini L., Chiarantini L., Palma P. & G. Crescentini (1985). 
Simultaneous extraction and reverse-phase high-performance liquid 
chromatographic determination of adenine and pyridine nucleotides in human 
red blood cells. Anal. Biochem. 146, 118–124. 
Swerdlow R.H. & Khan S.M. A “mitochondrial cascade hypothesis” for sporadic 
Alzheimer’s disease. Med Hypotheses 63:8-20 (2004). 
Swerdlow R.H. & S.M. Khan (2009). The Alzheimer's disease mitochondrial cascade 
hypothesis: an update. Exp Neurol 218:308-15. 
Swerdlow R.H. (2007). Pathogenesis of Alzheimer's disease. Clin Interv Aging 
2(3):347-59. 
Swerdlow R.H., Parks J.K., Cassarino D.S., Maguire D.J., Maguire R.S., Bennett J.P. Jr, 
Davis R.E. & W.D. Jr. Parker (1997). Cybrids in Alzheimer's disease: a cellular 
model of the disease? Neurology 49:918-25. 
Terman A., Gustafsson B. & U.T. Brunk (2006). Mitochondrial damage and 
intralysosomal degradation in cellular aging. Mol Aspects Med 27:471-82. 
Trimmer P.A. & M.K. Borland (2005). Differentiated Alzheimer's disease 
transmitochondrial cybrid cell lines exhibit reduced organelle movement. 
Antioxid Redox Signal 7:1101-9. 
Trimmer P.A., Keeney P.M., Borland M.K., Simon F.A., Almeida J., Swerdlow R.H., 
Parks J.P., Parker W.D. Jr. & J.P. Jr. Bennett (2004). Mitochondrial 
 abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with 
passage in culture. Neurobiol Dis 15:29-39. 
Trimmer P.A., Swerdlow R.H., Parks J.K., Keeney P., Bennett J.P. Jr. & S.W. Miller 
(2000). Abnormal mitochondrial morphology in sporadic Parkinson's and 
Alzheimer's disease cybrid cell lines. Exp Neurol 162:37-50. 
Valla J., Schneider L., Niedzielko T. Coon K.D., Caselli R., Sabbagh M.N., Ahern G.L., 
Baxter L., Alexander G., Walker D.G. & E.M. Reiman (2006). Impaired platelet 
mitochondrial activity in Alzheimer's disease and mild cognitive impairment. 
Mitochondrion  6:323-30. 
Vaquero A, Scher M.B., Lee D.H., Sutton A., Cheng H.L., Alt F.W, Serrano L., 
Sternglanz R. & D. Reinberg (2006). SirT2 is a histone deacetylase with 
preference for histone H4 Lys 16 during mitosis. Genes Dev 20:1256-61. 
Vulih-Shultzman I., Pinhasov A., Mandel S., Grigoriadis N., Touloumi O., Pittel Z. & I. 
Gozes (2007). Activity-dependent neuroprotective protein snippet NAP reduces 
Tau hyperphosphorylation and enhances learning in a novel transgenic mouse 
model. Pharmacol Exp Ther 323:438-49.  
Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, Casadesus G. & X. Zhu 
(2008). Amyloid-beta overproduction causes abnormal mitochondrial dynamics 
via differential modulation of mitochondrial fission/fusion proteins. Proc Natl 
Acad Sci U S A 105:19318-23. 
Wang X., Su B., Fujioka H. & X. Zhu (2008). Dynamin-like protein 1 reduction 
underlies mitochondrial morphology and distribution abnormalities in fibroblasts 
from sporadic Alzheimer's disease patients. Am J Pathol 173:470-82. 
 Wang X., Su B., Zheng L., Perry G., Smith M.A. & X. Zhu (2009). The role of 
abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J 
Neurochem 1:153-9. 
Westermann B. (2009). Nitric oxide links mitochondrial fission to Alzheimer's disease. 
Sci Signal 2:29. 
Wharton D.C. & A. Tzagotoff (1967). Cytochrome oxidase from beef heart 
mitochondria. Methods Enzymol. 10, 245–250. 
Yang D.S., Kumar A., Stavrides P., Peterson J., Peterhoff C.M., Pawlik M., Levy E., 
Cataldo A.M. & R.A. Nixon (2008). Neuronal Apoptosis and Autophagy Cross 
Talk in Aging PS/APP Mice, a Model of Alzheimer’s Disease. Am J Pathol 
173:665-81. 
Yu J. & J. Auwerx (2009). The role of sirtuins in the control of metabolic homeostasis. 
Ann N Y Acad Sci 1173 Suppl 1:E10-9. 
Yu W.H., Cuervo A.M., Kumar A., Peterhoff C.M., Schmidt S.D, Lee JH, Mohan PS, 
Mercken M., Farmery M.R., Tjernberg L.O., Jiang Y., Duff K., Uchiyama Y., 
Näslund J., Mathews P.M., Cataldo A.M. & R.A. Nixon (2005). 
Macroautophagy - a novel Beta-amyloid peptide-generating pathway activated 
in Alzheimer's disease. J Cell Biol 171:87-98. 
Yu W.H., Kumar A., Peterhoff C., Shapiro Kulnane L., Uchiyama Y., Lamb B.T., 
Cuervo A.M. &  R.A. Nixon (2004).  Autophagic vacuoles are enriched in 
amyloid precursor protein-secretase activities: implications for β-amyloid 
peptide over-production and localization in Alzheimer’s disease. Int J Biochem 
Cell Biol 36:2531-40. 
Zemlyak I., Furman S., Brenneman D.E. & I. Gozes (2000). A novel peptide prevents 
death in enriched neuronal cultures. Regul Pept 96(1-2):39-43. 
 Zemlyak I., Sapolsky R. & I. Gozes (2009). NAP protects against cytochrome c release: 
inhibition of the initiation of apoptosis. Eur J Pharmacol 618:9-14. 
Zhang Y., Tian Q., Zhang Q., Zhou X., Liu S. & J.Z. Wang (2009). 
Hyperphosphorylation of microtubule-associated Tau protein plays dual role in 
neurodegeneration and neuroprotection. Pathophysiology 16:311-6. 
Zheng L., Marcusson J. & A. Terman (2006). Oxidative Stress and Alzheimer Disease: 
the Autophagy Connection? Autophagy 2:143-5. 
